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ABSTRACT
Dynamic treatment regimes (DTRs) have gained increasing interest in the field
of personalized health care in the last two decades, as they provide a sequence of
individualized decision rules for treating patients over time. In a DTR, treatment is
adapted in response to the changes in an individual’s disease progression and health
care history.
However, specific challenges emerge when applying the current methods of DTR
in practice. For example, a treatment decision often happens after a medical test,
and is thus nested within the decision of whether a test is needed or not. Such
nested test-and-treat strategies are attractive to improve cost-effectiveness. In the
first project of this dissertation, we develop a Step-adjusted Tree-based Learning
(SAT-Learning) method to estimate the optimal DTR within such a step-nested
multiple-stage multiple-treatment dynamic decision framework using test-and-treat
observational data. At each step within each stage, we combine a doubly robust
semiparametric estimator via Augmented Inverse Probability Weighting with a tree-
based reinforcement learning procedure to achieve the counterfactual optimization.
SAT-Learning is robust and easy to interpret for the strategies of disease screening
and subsequent treatments when necessary. We applied our method to a Johns Hop-
kins University prostate cancer active surveillance dataset to evaluate the necessity
of prostate biopsy and identify the optimal test-and-treatment regimes for prostate
cancer patients.
xiii
Our second project is motivated by scenarios in medical practice where one need to
decide on patients radiation or drug doses over time. Due to the complexity of contin-
uous dose scales, few existing studies have extended their methods of multi-treatment
decision making to a method to estimate the optimal DTR with continuous doses. We
develop a new method, Kernel-Involved-Dosage-Decision learning (KIDD-Learning),
which combines a kernel estimation of the dose-response function with a tree-based
dose-search algorithm, in a multiple-stage setting. At each stage, KIDD-Learning re-
cursively estimates a personalized dose-response function using kernel regression and
then identifies the interpretable optimal dosage regime by growing an interpretable
decision tree. The application of KIDD-Learning is illustrated by evaluating the dy-
namic dosage regimes of the adaptive radiation therapy using a Michigan Medicine
liver cancer dataset.
In KIDD-Learning, our algorithm splits each node of a tree-based decision rule
from the root node to terminal nodes. This heuristic algorithm may fail to identify
the optimal decision rule when there are critical tailoring variables hidden from an
imperceptible parent node. Therefore, in the third project, we propose an important
modification of KIDD-Learning, Stochastic Spline-Involved Tree Search (SSITS), to
estimate a more robust optimal dosage regime. This new method uses a simulated
annealing algorithm to stochastically search the space of tree-based decision rules.
In each visited decision rule, a non-parametric smooth coefficient model is applied
to estimate the dose-response function. We further implement backward induction
to estimate the optimal regime from the final stage in a reverse sequential order
to previous treatment stages. We apply SSITS to determine the optimal dosing





Personal health care has gained increasing attention in recent decades (Collins and
Varmus , 2015; Niculescu et al., 2019). Compared with the traditional “one-size-fits-
all” paradigm, this medical approach allows physicians to consider the heterogeneity
of patients and yields more precise treatment recommendations and better disease
management. (Shi et al., 2020)
In particular, when managing a chronic disease, a personalized disease manage-
ment plan may involve multiple cycles of treatments, and the treatment in each cycle
is chosen adaptively based on patients’ history and time-varying characteristics (Lee
et al., 2015). This paradigm is known as a Dynamic Treatment Regime (DTR) (Mur-
phy , 2003; Wang et al., 2012), in which the entire sequence of decisions is evaluated,
rather than evaluating each treatment separately. Identifying optimal DTRs offers
an effective tool for personalized management of diseases, and helps physicians tai-
lor the treatment strategies dynamically and individually based on clinical evidence,
which provides a key foundation for enhanced care of chronic disease. (Murphy , 2003;
Chakraborty and Murphy , 2014).
However, it is challenging to develop a method for identifying the optimal dynamic
treatment regime due to the complex relationship between the clinical outcomes and
the accumulated time-varying treatment information. The time-varying confounders
1
should be carefully adjusted because the standard regression methods may fail to
address this complexity. Some pioneering statistical methods have been developed
to estimate the optimal DTRs, such as the G-estimation of structural nested mean
models (Robins , 1986, 1989), the Marginal Structural Model estimated with the in-
verse probability weighting (Robins et al., 2000; Robins , 2004), the Marginal Mean
Model (Murphy et al., 2001; Murphy , 2003), and other likelihood-based methods
(Thall et al., 2007). These methods often require a parametric or semi-parametric
conditional model for the counterfactual outcome as a component and thus can be
vulnerable to model mis-specification, especially when the data are high dimensional.
More recently, as an alternative for parametric or semi-parametric models, ma-
chine learning-based approaches have become increasingly popular because of their
flexibility in model assumptions and their robustness against model misspecification.
Examples include Q-learning (Watkins and Dayan, 1992), A-learning (Murphy , 2003;
Schulte et al., 2014), and the backward outcome weighted learning (Zhao et al., 2015;
Chen et al., 2018), all of which use backward induction to first optimize the decision
rule for the final stage, and then optimize the decisions of the previous stages in a
reversed sequential order.
However, specific research questions in clinical practice cannot be addressed when
applying the current methods of DTR. Therefore, in this dissertation, we aim to
continue this research direction and develop three robust and interpretable statisti-
cal learning methods to estimate the optimal DTR for various types of decisions in
multiple-stage settings. In particular, we use the counterfactual framework of causal
inference (Robins , 1986), and estimate the optimal DTR by maximizing the expec-
tation of the counterfactual outcome. Furthermore, due to the need applying these
innovative statistical learning methods to medical practice, a robust and interpretable
method for estimating the optimal DTR is highly desirable, as it bridges the gap be-
tween the physician’s medical expertise and the data-driven individualized treatment
2
regimes, and allows a physician to better understand and apply them.
Our first project as presented in Chapter II considers handling a special but im-
portant test-and-treat decision strategy in the application of DTR. It is motivated by
the example of the active surveillance of prostate cancer (Lange et al., 2018; Tosoian
et al., 2015). For prostate cancer patients, a decision about treatment happens after
the biopsy, and is thus nested within the decision of whether to do the biopsy test.
Considering the substantial side-effects of over-treatment and unnecessary biopsy
screening, the active surveillance, which involves closely watching patients’ disease
conditions but not giving any treatment unless significant progression is found, has
been increasingly recommended to patients with low risk prostate cancer (Denton
et al., 2019). However, the one-size-fits-all active surveillance plan is not individual-
ized for patients with heterogeneity. For example an older male in good health might
tolerate the invasive biopsy test, while a younger man might not be appropriate to
be monitored under the same active surveillance schedule because of his comorbidi-
ties (Loeb et al., 2014). A personalized sequence of an active surveillance plan, i.e.,
the biopsy test and definitive treatment plan, is a paradigm that actually resembles
a DTR, as it accounts for patients’ time-varying characteristics. However, the cur-
rent DTR methods cannot accommodate such a naturally embedded property of the
treatment decision within the test decision. Therefore, we developed a new statistical
learning method to evaluate DTRs within such a nested multi-stage dynamic decision
framework using observational data. At each step within each stage, we combined the
robust semi-parametric estimator via Augmented Inverse Probability Weighting with
a tree-based reinforcement learning method to deal with the counterfactual optimiza-
tion. The proposed method can handle test-and-treat observational data and estimate
an interpretable and robust optimal DTR for the strategies of disease screening and
subsequent treatments if necessary.
The second (Chapter III) and third project (Chapter IV) focus on estimating the
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optimal DTR with continuous treatment options in a multiple-stage setting. This re-
search direction is motivated by the study of Michigan Medicine liver cancer adaptive
stereotactic body radiation therapy (SBRT). In this study, the liver cancer patients
were treated with adaptive SBRT with an intra-treatment evaluation (Feng et al.,
2018). The previous data analysis of this study has shown the benefit of this innova-
tive adaptive SBRT in terms of improving overall survival probability and controlling
the incidence of local progression (Feng et al., 2013). Physicians are now interested
in the optimal personalized dose schema for a future trial under this adaptive SBRT
framework. That is, what dose should be given for patients for the first stage, and
should patients terminate the SBRT after the first stage due to high toxicity? If the
treatment continues, what is the radiation dose for the second stage, based on the
patients’ individualized time-varying characteristics?
How to estimate the optimal dosage regime within a multiple-stage setting is a
common research question in oncology when treating cancer patients with radiation
or drug doses over time. However, it is complex to extend the existing methods for
multiple-treatment to personalized dose-finding because of the sparse nature of the
observed data, i.e., the dose level follows a continuous distribution – of which the
probability of observing a specific dose is zero (Chen et al., 2016). Although consid-
erable research has been devoted to estimating multiple-stage DTRs with multiple
treatments in the literature, less attention has been paid to the estimation of DTRs
with continuous treatment options (Lee et al., 2015; Chen et al., 2016; Rich et al.,
2016; Schulz and Moodie, 2020). In Chapter III and Chapter IV, we develop two
methods, Kernel-Involved-Dose-Decision Learning (KIDD-Learning) and Stochastic
Spline-Involved Tree Search (SSITS), to estimate the optimal DTR with continuous
doses. In particular, in KIDD-Learning, a non-parametric kernel regression is uti-
lized to estimate a robust continuous dose-response function while in SSITS a flexible
smooth coefficient model is applied to evaluate the continuous dose effect. Both of
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the non-parametric methods are combined with flexible dose-search statistical learn-
ing methods to identify the optimal continuous dosage regime in the setting of a
multiple-stage DTR.
In addition to the robust non-parametric estimation of the dose-response func-
tion, the choice of dose-search methods of SSITS and KIDD-Learning is another
critical contribution of this dissertation. Since an interpretable treatment regime is
straightforward for physicians to understand, we believe a tree-based decision rule
is an appropriate choice for the desired interpretability. Therefore in the second
project (Chapter III), we use a tree-based dose-search algorithm to identify the op-
timal dosing strategy. This algorithm, which is derived from the Classification and
Regression Tree (CART) (Breiman et al., 1984; Laber and Zhao, 2015), yields a tree-
based dose decision rule by categorizing patients into different sub-population based
on their characteristics. When combining the algorithm with the estimation of the
dose-response function as the KIDD-Learning method, the satisfactory performance
is illustrated by comprehensive simulation studies .
However, from the simulations studies, we found that in some cases, when there
are strong predictors hidden from a relatively weak parent node, KIDD-Learning may
end up estimating a sub-optimal tree-based decision rule. This limitation is derived
from the heuristic nature of the CART, which is used in the dose-search algorithm
in KIDD-Learning. Such a top-down algorithm generates a sequence of trees, each of
which is a direct extension of the previous decision tree, which will inevitably result
in a locally optimal tree if the parent node is an imperceptible variable. Therefore,
in Chapter IV, we propose an improvement of KIDD-Learning based on a stochastic
dose-search algorithm, SSITS, for estimating the optimal dosage regime. Rather than
searching heuristically for the optimal dose from the root node to the terminals, SSITS
stochastically visits a broader binary decision tree space via the simulated annealing
algorithm and then determines the optimal dosing strategy. Compared to its CART
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counterpart, SSITS can efficiently search tree space more widely to escape from a
local optimal decision rule while still delivering the optimal DTR with satisfactory
interpretability. The outstanding stable performance of SSITS is well demonstrated
in the simulation studies.
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CHAPTER II
Step-adjusted Tree-based Reinforcement Learning
for Evaluating Nested Dynamic Treatment
Regimes with Test-and-Treat Observational Data
2.1 Introduction
Dynamic treatment regimes (DTRs) have gained increasing interest in the field
of precision medicine in the last decade (Chakraborty and Murphy , 2014). This re-
search direction generalizes the individualized medical decisions into a time-varying
treatment setting, usually at discrete stages, and thus accommodates the updated in-
formation for each person at each stage (Murphy , 2003; Wang et al., 2012). In DTR,
actions or decisions based on the individualized features are able to lead to more pre-
cise disease prevention and better disease management. However, the current DTR
framework is limited because it only considers choosing the best treatments strate-
gies. In medical practice, the procedures to diagnose and treat patients are much
more complicated. Most diagnosis procedures or tests, e.g., positron emission tomog-
raphy, or a biopsy test, occur prior to the selection of treatment to provide more
information about disease status, then this information would be used to select treat-
ment. Typically, only patients who have taken the test can be treated, and thus the
decision about the treatment assignment is nested within the decision of performing
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the test.
For example, men with early stage asymptomatic prostate cancer who are in
an active surveillance program, would regularly have their prostate-specific antigen
(PSA) and prostate tissue measured via a blood test and core needle biopsy test
respectively (Loeb et al., 2014). Whether to undergo definitive treatment for their
prostate cancer would be strongly influenced by the results from their biopsy test. So
the possible treatment initiation only happens after having the biopsy test result, and
is thus nested within the decision of doing a biopsy or not. Such a nested dynamic
clinical decision-making is not limited to prostate cancer. The occult blood test, also
known as a stool test, can also be used as a cheap and easy initial screening test for
colorectal cancer (Itzkowitz et al., 2008). Patients with abnormal finding from the
stool test are then referred for a colonoscopy exam, which is costly and invasive, to
confirm the diagnosis and decide if more definitive treatment for colorectal cancer is
needed. In this scenario the decision of whether to do definitive treatment is nested
in the decision of whether to do a colonoscopy which is nested within the decision to
do a stool test or not. This kind of nested clinical decision also happens with many
other chronic diseases. (US Preventive Services Task Force, 2009; Mandelblatt et al.,
2009; Hanley , 2011)
In such nested test-and-treat scenarios, the impact of the test should also be
considered. For some diseases, the tests used to confirm the diagnosis or decide
on the next step are easy to administer and minimally invasive, e.g., blood test
and physical examination. But some other tests done for confirmatory purposes are
expensive and invasive, including the prostate biopsy and colonoscopy. The potential
side effects include pain, soreness, and infections, which should not be overlooked. For
prostate cancer, even if the test result suggests progressive disease, it is not always
the case that the patient should undergo definitive treatment, which has substantial





















Figure 2.1: Hypothetical step-adjusted DTR framework with a treatment step nested
within the test step of each intervention stage.
of men may not develop deadly prostate cancer before dying from some other cause.
It is well known that there is overtreatment for prostate cancer, and that a substantial
number of men receive unnecessary cancer treatments (Loeb et al., 2014). Therefore,
careful patient selection for testing is needed to not only reduce the impact on the
patient, but also to save medical resources for the patients who truly need them. The
current one-fits-all active surveillance protocol is not capable of taking the patient’s
personalized medical characteristics into account and then giving an individualized
disease management plan.
As mentioned above, most existing frameworks for evaluating DTRs overlook such
nested structures during the clinical decision making process. The diagnostic test it-
self does not have a direct impact on the disease-related outcome, but the potential
treatment following the test may improve the disease outcome for the patient sub-
stantially (Trikalinos et al., 2009). Overlooking such a test-and-treat nested structure
may result in identifying imprecise and non-realistic decision rules. Therefore, we pro-
pose a new nested dynamic treatment regime (nested-DTR) framework by embedding
the treatment step within the test step of each intervention stage as shown in Fig-
ure 2.1. At each stage, the decision of the test step is made based on the health
history and the treatment decision is made on the basis of previous health history
and the updated history after the test.
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In general, DTRs can be estimated from observational data, provided there is
enough heterogeneity in the patient features and their actions taken. Similarly the
optimal DTR for this new nested-DTR framework can be learned from observational
data provided there is enough heterogeneity in data for both the decision to test and
the decision to treat.
A great number of statistical methods have been developed to estimate the optimal
DTRs using observational data, such as Marginal Structural Model estimated with
inverse probability weighting (Robins , 2004), the Marginal Mean Model (Murphy
et al., 2001) and other likelihood-based methods (Thall et al., 2007). These methods
require a parametric or semi-parametric conditional model for the counterfactual
outcome as a component and thus are vulnerable to model mis-specification, especially
when the data are high dimensional or time-dependent information is accumulated.
More recently, machine learning-based approaches, as a replacement for parametric or
semi-parametric models, have become increasingly popular because of their flexibility
in model assumptions and their robustness (Laber et al., 2014; Zhao et al., 2015).
When identifying the optimal DTRs with multiple stages, the problem resembles the
reinforcement learning (RL) problem (Watkins and Dayan, 1992). Therefore, RL
methods are currently broadly applied in evaluating the optimal DTRs. Some of
this work, which involving reinforcement learning, has focused on developing easily
interpretable DTRs for real-world practice (Shen et al., 2017; Tao and Wang , 2017;
Tao et al., 2018; Schulte et al., 2014; Zhang et al., 2015).
To the best of our knowledge, however, none of the existing methods can be applied
directly to estimate the optimal DTRs when each stage consists of a treatment step
nested within a test step. In this paper, we are trying to fill this gap and develop a
new statistical learning method for identifying the optimal DTR within the nested
dynamic decision framework. At each step within each stage, we combine the robust
semi-parametric estimator obtained using Augmented Inverse Probability Weighting
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(AIPW) with a modified tree-based reinforcement learning method to optimize the
expected counterfactual outcome. The remainder of this paper is organized as follows:
In 2.2 and 2.3, we formalize the problem of identifying the optimal DTR within the
nested DTR framework in a multiple-stage multiple-step setting from observational
data and develop the nested step-adjusted tree-based reinforcement learning method
(SAT-Learning). Section 4 presents the detailed implementation of this new method.
Numerical simulation studies and an application to the Johns Hopkins University
(JHU) prostate cancer active surveillance data are provided in 2.5 and 2.6. We
conclude with a brief discussion in Section 2.7.
2.2 Multi-Stage Nested Step-Adjusted Dynamic Treatment
Regimes
To address the nested decision problem above, we consider a nested multi-stage
multi-step decision framework with S decision stages. In clinical practice, every
regular clinic visit, which might initiate some form of treatment, can be considered as
a stage. Within each stage s, there are J action steps. Let Ksj denote the number of
decision options at step j of stage s (Ksj ≥ 2), let Dsj denote the multiple treatment
indicators of the action taken at step j of stage s in the observed data, and the value
of Dsj is dsj ∈ Dsj. Without loss of generality, we consider two steps within each
stage, i.e., J = 2, to make the presentation easier. We assume the first step of stage
s is the test step (action Ds1) and Ds2 in the treatment step is nested within the
decision of Ds1. For example, only the prostate cancer patients who have had the
biopsy test are considered for further treatment. We denote the patient’s history prior
to action Dsj but after the previous step as Xsj. We will use overbar with subscripts
s and j to denote a vector of a variables’s history up to the step j of stage s. For
example, Xs2 = (X11, X12, X21, . . . , Xs1, Xs2). Similarly, the action history up to the
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treatment step of stage s can be denoted as Ds2 = (D11, D12, D21, . . . , Ds1).
We use Ysj to denote the intermediate reward outcome at the end of step j of
the stage s, and thus the overall rewards vector is (Y11, Y12, . . . YS2) . The outcome of
interest Y is a function of all rewards, i.e., Y = f(Y11, Y12, Y21, . . . YS2), where f(·) is a
pre-specified function (e.g., sum). We also assume that Y is bounded and high values
of Y are desirable. The observed data before stage s step j (1 ≤ s ≤ S, 1 ≤ j ≤ 2)
are
{X11, D11, Y11, X12, . . . , Ds−1,2, Ys−1,2, Xs1}ni=1 ≡ {Xs1, Ds−1,2, Y s−1,2}ni=1
for step 1 , and
{X11, D11, Y11, X12, . . . , Xs1, Ds1, Ys1, Xs2}ni=1 ≡ {Xs2, Ds1, Y s1}ni=1
for step 2. For brevity, we suppress the subject index i in the following text when no
confusion exists. The observed data are assumed to be independent and identically
distributed for n subject from the population of interest. The history Hsj is defined
as the test results and action history prior to the action assignment Dsj. To be more
specific, Hs1 = (Ds−1,2, Xs1, Y s−1,2) and Hs2 = (Ds1, Xs2, Y s1). To illustrate the
method, we also specify two action options in the test step and three options in the
treatment step of every stage, i.e., ds1 ∈ Ds1 = {0, 1}, Ks1 = 2, and ds2 ∈ Ds2 =
{0, 1, 2}, Ks2 = 3. When a patient has dsj = 0, i.e. no treatment or test is given, he/
she will still be kept in the study cohort but not given further treatment until the next
stage s + 1. Thus, the reward is Ysj = 0 when dsj = 0. For the data collected from
the active surveillance study , if the patient receives treatment in some treatment
step, i.e., ds2 = 1 or 2, he will be removed from the study according to the active
surveillance protocol.
With a treatment step nested after every test step within a stage, the nested DTR
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is defined as a personalized test-and-treatment rule sequence. The rule is based on
the observed history Hsj about the patient’s health status up to the action in step j
of stage s. Let g denote the above nested DTR. Formally, g = (g11, g12, . . . , gS2) is
defined by a collection of mapping functions, where gsj is mapped from the domain
of history Hsj to the domain of Dsj, i.e.,
Hsj 7→ gsj(Hsj) ∈ Dsj, 1 ≤ s < S, 1 ≤ j ≤ 2
2.3 Step-adjusted Optimization for Nested DTR
Let Y ∗(g) be the counterfactual outcome if all patients follow g to assign treatment
or test conditional on previous history. The performance of g is measured by the
counterfactual mean outcome E{Y ∗(g)} conditional on the patients’ history. We
denote the optimal regime as gopt. Our goal of identifying the optimal regime is to
find the gopt which satisfies
E{Y ∗(gopt)} ≥ E{Y ∗(g)}
for all g ∈ G, where G is the set of all potential regimes.
2.3.1 Optimization of gS2 and gS1 for the Final Stage S
The approach to finding optimal DTR includes backward induction (Murphy et al.,
2001), therefore we illustrate the mathematical formulation from the last stage S. For
the last step of the stage, let Y ∗S2(dS2) be the counterfactual outcome if a patient makes
treatment decision dS2 conditional on previous history. We denote the optimal regime
as goptS2 , which satisfies E{Y ∗S2(goptS2 )} ≥ E{Y ∗S2(gS2)} for all gS2 ∈ GS2, where GS2 is the
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set of all potential regimes at stage S and step 2.
To connect the counterfactual outcome with observed data {XS2, DS2, Y S2}, we
make the following standard causal inference assumptions (Murphy , 2003; Orellana
et al., 2010):
1. Consistency. The observed outcome coincides with the counterfactual outcome




Y ∗S2(dS2)I{gS2(HS2) = dS2}I{dS1 = 1},
where I(·) is the indicator function that takes the value 1 if · is true and 0
otherwise. The indicator function I(dS1 = 1) implies only the subjects who
decided to take the previous test, i.e., dS1 = 1, can have their YS2 observed.
2. No unmeasured confounding. The observed action DS2 is independent of poten-
tial counterfactual outcomes conditional on the history HS2, i.e.,
DS2 ⊥ {Y ∗S2(0), Y ∗S2(1), Y ∗S2(2)} | HS2,
where ⊥ denotes statistical independence. This assumption implies that the
potential confounders are fully observed and included in the dataset.
3. Positivity. For the observational data, the propensity score pidS2(HS2), the
probability of receiving a certain treatment conditional on history, is bounded
away from 0 and 1, i.e., pidS2(HS2) = Pr(DS2 = dS2 | HS2) ∈ [c1, c2], where
0 < c1 < c2 < 1.
For the subjects who do not have the test in the previous step, i.e., dS1 = 0, their test
result that the further treatment decision is based on cannot be observed. Therefore,
only the subjects with dS1 = 1 is able to contribute to the optimization of gS2. Under
the three assumptions, the optimization problem for the treatment of the last stage
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becomes





E(YS2 | DS2 = dS2,HS2)




where EHS2(.) denotes the expectation with respect to the marginal joint distri-
bution of the observed history HS2. To derive the optimal g
opt
S1 for whether to
take the test, i.e., one step before the treatment step within the same stage S,
we utilize the backwards induction (Murphy , 2003). In addition to the counter-
factual outcome of stage s step j Y ∗sj defined in the last section, we also define a
nested step-adjusted future optimized counterfactual outcome Y˜ ∗S1. More specifi-
cally, we have Y˜ ∗S1 = {Y ∗(DS−1,2, gS1, goptS2 )}, where the treatment for stage S step
2 has been optimized. To determine the optimal goptS1 , we propose to maximize
the expected nested step-adjusted future optimized counterfactual outcome Y˜ ∗S1, i.e.,
goptS1 = arg maxgS1∈GS1 EHS1 [{Y ∗(DS−1,2, gS1, goptS2 )}].
Similarly, we assume No Unmeasured Confounding, DS1 ⊥ {Y˜ ∗S1(0), Y˜ ∗S1(1)} |
Hs1 , if dS1 = 1, and if dS1 = 0, DS1 ⊥ {Y ∗S1(0), Y ∗S1(1)} | Hs1 ; Positivity pidS1(HS1) =
Pr(DS1 = dS1 | Hsj) ∈ [c1, c2], where 0 < c1 < c2 < 1; and then the optimization
problem of stage S step 1 can be written as






E[Y˜ ∗S1 | DS1 = dS1,HS1]I(dS1 = 1)






Different from Eqn (2.1), the optimization process Eqn (2.2) of goptS1 is conducted
within all eligible subjects, while the optimization of goptS2 is conducted only within
the patients who have the test at the previous step. Although the whole cohort
contributes to the optimization step in Eqn (2.2), Y˜ ∗S1 or Y
∗
S1 used in Eqn (2.2) actually
depends on the test decision, i.e., dS1. The subjects who had the test, i.e., dS1 = 1,
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essentially have one more chance to optimize their rewards through stage S step 2
compared to those without test, and this chance is nested within the positive exam
decision within the same stage.
2.3.2 Optimization of gs2 and gs1 for Any Stage Before S
For the steps of stage s before the last stage (1 ≤ s < S), the optimal regime
gopts1 and g
opt
s2 is expressed via backward induction as well. Y˜
∗
sj is defined as the nested
step-adjusted future optimized counterfactual reward, which is given that all future
stages’ and steps’ actions are already optimized. More specifically, we have Y˜ ∗s1(gs1) =
{Y ∗(Ds−1,2, gs1, gopts2 , . . . , goptS2 )} and Y˜ ∗s2(gs2) = {Y ∗(Ds1, gs2, gopts+1,1, . . . , goptS2 )}. Similar
to the assumptions for the last stage, we assume No Unmeasured Confounding and
Positivity. Under these assumptions, the optimization problems at stage s step j can
be written as


















2.4 Step-adjusted Tree-based Reinforcement Learning and
its Implementations
Given the observational data with test-and-treat nested decision structure, we pro-
pose to solve Eqn (2.1), Eqn (2.2), Eqn (2.3), and Eqn (2.4) through the step-adjusted
tree-based learning (SAT-Learning) method. In this method, the step-adjusted future
optimized pseudo-outcome is iteratively inducted backwards. We further assume, for
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stages and steps before the last step, i.e., for any s < S, j = 1 or 2,, the effect of
intermediate outcome reward Ysj will be cumulatively carried forward to the final
outcome (Huang et al., 2015), and denote a nested step-adjusted future optimized
pseudo-outcome of stage s step j as POsj. Let µsj,dsj(Hsj) = Ê[POsj | Dsj = dsj,Hsj]
be the estimated mean pseudo-outcome of stage s step j. Because of the cumulative
property of the reward outcome and the nested connection between the test step and
the treatment step, for any s < S, j = 1 or 2, POsj can be expressed in a recursive
form as POs1 = Ys1 +
∑S
r=s µr2,goptr2




POs2 = Ys1 +
∑S
r=s+1[µr2,goptr2
(Hr2) × I(dr1 = 1) + µr1,goptr1 (Hr1)]. Obviously, when
evaluating the pseudo-outcome in last stage, we have POS2 = YS2 for the second step
and POS1 = Ys1 + µS1,goptS1
(HS1)× I(dS1 = 1) for the first step.
To reduce the accumulated bias from the conditional mean models, instead of
using the model-based values under optimal future treatments µ̂sj,dsj(Hsj) = Ê[POsj |
Dsj = dsj,Hsj] from POsj, we use the actual observed intermediate outcomes plus
the expected future loss (or gain) due to the sub-optimal treatments as the modified
pseudo-outcome PO′sj (Huang et al., 2015). Specifically, the modified pseudo-outcome
of the last stage is PO′S2 = YS2, PO
′
S1 = YS1 +µS2,goptS2
(HS2)−µS2,DS2(HS2) +YS2 and






(Hr1)− µr1,Dr1(Hr1) + Yr1
+ I[dr1 = 1][µr2,goptr2
(Hr2)− µr2,Dr2(Hr2) + Yr2]
]
+ Ysj + I[j = 1]I[dsj = 1]
[
µs2,gopts2
(Hs2)− µs2,Ds2(Hs2) + Ys2
]
(2.5)
In particular, if the subject undergoes the test at stage s, i.e., ds1 = 1, he/she might
benefit from the potential subsequent treatment within that stage via the optimization
of the future treatment step. If the subject does not receive the test at stage s, then
his/her future optimized counterfactual outcome can only be optimized through the
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optimal actions of the future stages.
We propose to implement SAT-Learning through a modified version of a tree-
based reinforcement learning method (T-RL) (Tao et al., 2018), which employs the
classification and regression tree (CART) proposed by Breiman et al. (1984). In the
nested DTR setting, we need to include the step-wise adjustment to account for the
nested test-and-treat nature. Thus, we developed a modified tree-based algorithm to
implement SAT-Learning for estimating the optimal nested DTR. Traditionally, the
decision tree of CART is built to choose a split that would have the purest child nodes.
The purest node means having the lowest misclassification rate among all possible
nodes. Thus, purity is a crucial measure to grow a decision tree. Different from
CART, SAT-Learning at each node selects the split to improve the counterfactual
mean reward, which can serve as a measure of purity in nested DTR trees, and then
maximizes the population’s counterfactual mean reward of interest. Similarly as in T-
RL, to estimate the optimal DTR, we use a purity measure for SAT-Learning based on
the augmented inverse probability weighting (AIPW) estimator of the counterfactual
mean outcome.
In the process of partitioning of this tree-based reinforcement learning method,
for a given partition ω and ωc of node Ω, let gsj,ω,d1,d2 denote the decision rule that
assigns a single test/treatment action d1 to all subjects in ω and treatment d2 to
subjects in ωc at stage s step j (1 ≤ s ≤ S, j = 1, 2). Then the purity measure can
be defined as









where Pn is the empirical expectation operator and Pn{µ̂AIPWsj,dsj (Hsj)} is the AIPW
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In Eqn (2.7), the propensity score model is denoted as pisj,dsj(Hsj) and the conditional
mean model is denoted as µsj,dsj(Hsj). Under the foregoing three causal inference
assumptions, Pn{µ̂AIPWsj,dsj (Hsj)} is a consistent estimator of the counterfactual mean
outcome E{Y ∗(dsj)} if either the propensity score model pisj,dsj(Hsj) or the conditional
mean model µsj,dsj(Hsj) is correctly specified. Thus this AIPW estimator is doubly
robust for estimating the counterfactual mean outcome of the population (Tao and
Wang , 2017).
In our nested step-adjusted multi-stage setting, for the last step of the last stage,
S2 , we have YS2 in Eqn (2.7) as the observed reward of the last step of the last stage.
For other stage s step j before the last one (1 ≤ s < S, j = 1, 2 ors = S , j = 1),
Ysj in Eqn (2.7) is replaced with PO
′
sj, the corresponding pseudo-outcome defined in
Eqn (2.5).
In the process of maximizing Psj(Ω, ω), the possible split ω of a given node Ω
should be either a subset of a categorical covariate categories or values that are not
larger than the threshold. The best criteria ω̂opt to split a given node is a partition
that is able to maximize the improvement in the purity, Psj(Ω, ω) − Psj(Ω), where
Psj(Ω) is for the situation where we assign the same single test/treatment action to
all subject in Ω, i.e., no splitting. To control the overfitting and also make practical
and meaningful splits, a positive integer n0 is specified as the minimal node size and
a positive constant λ is also provided as a threshold for the meaningful improvement.
Besides the two given constant values λ and n0, we apply similar Stopping Rules as
in Tao et al. (2018) to grow and split the tree. Our Stopping Rules can be found
in the Appendix as Algorithm 5. The depth of a node mentioned in the stopping
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rules is defined as the number of edges from the node to the tree’s root node, and
a root node has a depth of 0. The nested SAT-Learning algorithm given the above
purity measures and stopping rules of the partitioning is presented in Algorithm 1
with details. Note the essential difference between steps j=2 and j=1 is that different
subjects are included into the calculation of the AIPW estimator. Only the subjects
who have taken the test at stage s, i.e., ds1 = 1, contribute to the optimization of
their subsequent treatments.
Algorithm 1 Implementation Steps of SAT-Learning
Stage s Start the algorithm with s = S Within Stage s:
(1.1) Set j = 2 and only use the data with dsj = 1
(1.2) Obtain AIPW estimates µ̂AIPWsj,dsj (Hsj), dsj = 1, . . . , Ksj
(1.3) Set m = 1 at root node Ωsj,m




Pn[µ̂AIPWsj,dsj (Hsj)I(Hsj ∈ Ωsj,m)]
to all subject in Ωsj,m. Otherwise, split Ωsj,m into child nodes
Ωsj,2m and Ωsj,2m+1 by ω̂
opt.
(1.5) Set m = m+ 1 and repeat (1.4) until all nodes are terminal.
(2.1) Set j = 1 and use the full data and restrict the available nodes’
values according to Ps2(Ω, ω)
(2.2) Repeat Steps (1.2)-(1.5)
Next Stage: Set s = s− 1 and repeat Stage s: (1.1)-(2.2), stop if s = 1.
When implementing SAT-Learning process, the propensity score pisj,dsj(Hsj) in
Eqn (2.7) can be estimated by a multinomial logistic regression model. This working
model could incorporate linear main effect terms from history Hsj and summary
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variables or interaction terms based on prior scientific knowledge from individual
history Hsj. For continuous outcome, the conditional mean estimates µ̂sj,dsj(Hsj) in
Eqn (2.7) could be obtained either from a linear parametric regression model or from
other off-the-shelf non-parametric machine learning methods, such as random forests
or support vector regression, depending on the history Hsj and the test/treatment
action Dsj. For estimating the conditional mean model for binary or other count
outcomes, one could use a generalized linear models or other generalized classification
tools in machine learning.
2.5 Simulation Studies
2.5.1 Simulation Studies to Evaluate the General Test-and-treat Nested
DTR
We generate simulation study data that mimic the real-world observational test-
and-treat study. We assume a two-stage two-step nested dynamic treatment regime,
using Dsj with subscript value s = 1, 2 to represent the stage and j = 1, 2 to represent
the test and treatment action within each stage. More specifically, we set two options
in the test step as ds1 = 1 or 0 to indicate receiving the test or not, and three
treatment options in the treatment step as ds2 = 0, 1 or 2. We further define the
outcome of interest as the sum of intermediate rewards from each stage and step,
i.e., Y = Y11 + Y12 + Y21 + Y22. The underlying optimal treatment is supposed to
have the largest expected reward. The other two sub-optimal treatments have lower
expected rewards. We further consider two cases. One is that the expected reward
from the two sub-optimal treatments are equal while in the other case, the expected
reward of the two sub-optimal treatments are different. Therefore, in the second case,
the sub-optimal reward losses are different because patients may lose more treatment
benefit due to choosing one sub-optimal treatment compared to another.
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When the test step initiating each intervention step is not expensive or invasive,
more patients tend to choose such a test because they might benefit from knowing
the test result for the long term disease control purpose. However, when the lab test
is unpleasant and costly, such as a prostate biopsy test, the patients would hesitate
to take it. Therefore, when generating data we consider three scenarios based on
the patients’ willingness to receive the exam by modifying the parameters to set the
ratio of having or not having the test as 1:1, 2:1, and 1:2, which correspond to the
equal preference, more likely and less likely to take the exam, respectively. For these
three scenarios, three covariates, X1 to X3, generated as the baseline covariates fol-
low N(0, 1). Two correlated covariates, X4 and X5, are generated as time-varying
biomarkers which are measured just before the decision time of the test step within
each stage. (X4, X5)




the test step of each stage, the covariates X12 and X22 mimic the test results that
contribute to the treatment decision nested within each test decision with other co-
variates. Typically, the test results, such as biopsy results, are of great importance
to the treatment decision making. X12 and X22 follow the distribution of N(0, 1).
Details of parameter setting are as follows:
Stage 1: The test decision variables, D11 ∼ Bernoulli(pi11,1) with pi11,1 = exp(0.6X3−
0.2X2 +X4)/(1 + exp(0.6X3 − 0.2X2 +X4)). The reward of step 1 of stage 1 is gen-
erated as Y11 = X
2
4 + (0.5X3 + 3)
2 × I[gopt11 (H11) = D11]− 3|X1|I(D11 = 1) + 11 with
optimal regimes defined as
gopt11 (H11) =

I(X1 > −0.5)I(X4 ≤ 0.3) for Scenario 1
I(X1 > −0.8)I(X4 ≤ 1) for Scenario 2
I(X1 > 0.3)I(X4 ≤ 1.3) for Scenario 3,
and 11 ∼ N(0, 1). The Scenarios 1, 2, and 3 corresponds to patients’ equal preference,
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more likely, and less likely to take the test, respectively. For patients who have
taken the test, i.e., D11 = 1, we further generate the treatment assignment D12
for them as D12 ∼ Multinomial(pi12,0, pi12,1, pi12,2) with pi12,0 = 1/(1 + exp(0.5X12 −
0.2X2)+exp(0.2X4 +0.3X3)), pi12,1 = exp(0.5X12−0.2X2)/(1+exp(0.5X12−0.2X2)+
exp(0.2X4 + 0.3X3)) and pi12,2 = exp(0.2X4 + 0.3X3)/(1 + exp(0.5X12 − 0.2X2) +
exp(0.2X4 + 0.3X3)). Also, Y12 = I[D12 = g
opt
12 (H12)](2X12 + 3X2)
2 + (X1 +X3 ∗ 2 +
X4) + Y11/3 + 12 for equal sub-optimal reward loss; and
Y12 =I[D12 = g
opt
12 (H12)](2X12 + 3X2)
2 + (X1 +X3 ∗ 2 +X4) + Y11/3
+ 0.5I(D12 = 1)[I(g
opt
12 (H12) = 1)− 1] + 1.2I(D12 = 2)[I(gopt12 (H12) = 2)− 1]
+ 12
for unequal sub-optimal reward loss with 12 ∼ N(0, 1). The tree-type optimal regime
at step 2 is specified as
gopt12 (H12) =

0 X12 > 0.2
1 X1 > −0.7, X12 ≤ 0.2
2 otherwise.
Stage 2: We generate the test decision of stage 2, D21 ∼ Bernoulli (pi21,1) with
pi21,1 = exp(0.5X1− 0.6X2 +X3)/(1 + exp(0.5X1− 0.6X2 +X3)). The reward of stage
2 step 1 is generated as Y21 = X
2
5 + 2X1 + (X3 + 3.2)
2I[gopt21 (H21) = D21]− 3I(D21 =
1) + 21 with 21 ∼ N(0, 1). The optimal regime gopt21 (H21) is specified as
gopt21 (H21) =

I(X1 ≤ −0.3) + I(X1 > −0.3)I(X5 ≥ 1) for Scenario 1
I(X1 ≤ 0.4) + I(X1 > 0.4)I(X5 ≥ 1.2) for Scenario 2
I(X1 ≤ −0.8) + I(X1 > −0.8)I(X5 ≥ 1) for Scenario 3.
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Among the patients who have had the test, i.e., D21 = 1 we generate their treat-
ment assignment D22 for the second step of stage 2. Specifically, we generate treat-
ment D22 ∼ Multinomial(pi22,0, pi22,1, pi22,2) with pi22,0 = 1/(1 + exp(0.35X22 −X5) +
exp(0.3X2 +0.2X3)), pi22,1 = exp(0.35X22−X5)/(1+exp(0.35X22−X5)+exp(0.3X2 +
0.2X3)), and pi22,2 = exp(0.3X2+0.2X3)/(1+exp(0.35X22−X5)+exp(0.3X2+0.2X3)).
The reward of stage 2 step 2 is generated as Y22 = 3I[D22 = g
opt
22 (H22)] + Y21 + (2 +
X4X5 +X3) + 22 for equal sub-optimal reward loss; and
Y22 =(3 +X22)I[D22 = g
opt
22 (H22)] + Y21 + (2 +X4X5 +X3)
+ 2I(D22 = 1)[I(g
opt
22 (H22) = 1)− 1] + I(D22 = 2)[I(gopt22 (H22) = 2)− 1] + 22
for unequal sub-optimal reward loss, and 22 ∼ N(0, 1). The optimal treatment regime
for stage 2 gopt22 (H22) is specified as
gopt22 (H22) =

0 X22 > 0.5
1 X22 ≤ 0.5, X5 < 0.3
2 otherwise.
Table 2.1 summarizes the simulation study results across different scenarios as
described above. Our SAT-Learning method for estimating the optimal DTR in-
volves a doubly robust semi-parametric estimator, therefore our simulations also try
to demonstrate such robustness. In addition to having one estimation scheme with the
conditional mean model and the propensity score model both correctly specified, we
consider two more schemes with either the propensity score model or the conditional
mean model mis-specified by omitting some of the covariates of the true form. We
consider a sample size of either 1000 or 2000 for the training dataset, and a sample
size of 2000 for the validation, and repeat the simulation 500 times. The training
dataset is used to estimate the optimal regime and then predict the optimal test-and-
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Table 2.1: Simulation results for the general test-and-treat case for the equal and
unequal reward loss for sub-optimal treatment options: two intervention
stages, three treatment options at each stage nested within the exam at
each stage with 500 replications, and n=1000 or 2000.
Sample Size Sub-optiomal Scenario 1 (1:1) Scenario 2 (2:1) Scenario 3 (1:2)
Reward opt% opt% opt%
N=1000
(a) 90.1(7.4) 86.1(9.2) 91.9(6.3)
Equal Loss (b) 84.7(7.5) 81.0(7.9) 86.9(6.4)
(c) 90.1(7.6) 86.3(9.3) 92.1(6.4)
(a) 96.2(3.8) 96.3(4.0) 97.7(2.0)
Unequal Loss (b) 92.0(6.1) 87.5(12.5) 94.7(4.1)
(c) 96.0(4.1) 96.2(4.4) 97.6(2.2)
N=2000
(a) 91.2(7.5) 86.8(9.3) 93.2(6.4)
Equal Loss (b) 85.8(6.6) 81.9(6.3) 88.2(6.1)
(c) 91.1(7.5) 86.9(9.3) 93.2(6.4)
(a) 96.9(3.4) 97.7(2.7) 98.2(1.8)
Unequal Loss (b) 96.6(3.6) 93.8(8.8) 97.7(1.7)
(c) 96.9(3.4) 97.7(2.6) 98.1(1.8)
a. opt% show the empirical mean and standard deviation (SD) of the percentage of subjects
correctly classified to their underlying true optimal treatments
b. The optimal regimes are estimated by the proposed method when (a) the conditional mean
model and the propensity score model are both correctly specified, (b) the conditional mean model
is mis-specified and the propensity score model is correctly specified, and (c) the conditional mean
model is correctly specified and the propensity score model is mis-specified.
c. Scenarios 1,2 and 3, correspond to the cases when the true ratios of preference for having the
exam v.s. not having the exam among all patients are 1:1, 2:1 and 1:2.
treat decision in the validation dataset, where the underlying true optimal regimes
are already known. The percentages of subjects correctly classified to the optimal
test-and-treatment decision in both stages combined is denoted as opt%. The aver-
age opt% and the empirical standard deviation (SD) among the repetitions evaluate
the performance.
In Table 2.1, the results of equal sub-optimal reward case demonstrate the loss
due to sub-optimal equally inferior compared to the optimal choice. In scenario 1,
where the subjects have an even preference of having test, under the sample size
n=1000, 90.1% of the patients are correctly assigned to their optimal DTRs for both
stages when both the conditional mean model and the propensity score model are
correctly specified. When either the conditional mean model or the propensity score
model is mis-specified, but not both, the overall performances are slightly worse,
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but still reasonably satisfactory. More specifically, when either the propensity score
model or the conditional mean model is incorrectly specified, we still get 90.1% and
have 84.7% respectively. Similar trends are found in Scenario 2 and Scenario 3,
and results improve as sample size goes to N=2000. However, when the reward
loss is unequal among sub-optimal treatment options, the optimal regimes stand out
among the candidate treatments more obviously according to our data generating
process, therefore, it is easier for our proposed method SAT-Learning to distinguish
the optimal treatment from sub-optimal ones. Thus, the simulation performance
with varying sub-optimal loss is better than when the sub-optimal loss is equal, as
expected.
2.5.2 A Special Case when the Treated Patients no Longer Need Further
Test or Treatment
We conduct another simulation study for a special case when the treated pa-
tients no longer need test and treatment again. This simulation better mimics the
monitoring and management in active surveillance for prostate cancer. Because of
the significant side-effects of curative intervention and the asymptomatic nature of
prostate cancer, according to the American Society of Clinical Oncology, patients
with low-risk prostate cancer can consider active surveillance (Tosoian et al., 2011;
Klotz et al., 2014). Active surveillance involves monitoring prostate cancer by regular
exam in its localized stage until further treatment is needed to halt the disease at a
curable stage. More specifically, the patients who have taken the biopsy test, only
a small proportion of them would switch from the active surveillance to curative in-
tervention. In the active surveillance, the patients who have been treated should be
removed from the active surveillance cohort, because physicians consider that they
no longer need to be treated and additional treatment is not provided and they are
not eligible for the active surveillance. Therefore they should not be considered to
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evaluate the subsequent test or treatment decision. We generate data under a two-
stage nested DTR with two treatment options at each stage. We also modify the
parameters in the data generating models to make the rates of taking the curative
treatment equal to 5%, 15%, 20% and 25% in both stage. The higher the rate is, the
more patients take the treatment and thus more patients will be removed from the
surveillance afterwards. The detailed information of data generation can be found in
the Appendix
The simulation results are summarized in Table 2.2. As the results show, because
of the nice doubly robust property, the percentages of subjects correctly classified to
their underlying truth both yield satisfying results even when either the propensity
score model or the conditional mean model is mis-specified, but not both. Considering
sample size N=1000 as an example, when 5% of tested patients have the curative
treatment and then are removed from the active surveillance, 92.8% of them are
correctly assigned to their optimal DTR for both stages when both the conditional
mean model and the propensity score model are correctly specified. We also have
91.8% and 91.6% of the patients correctly classified to their optimal DTR when the
propensity score model or the conditional mean model is misspecified respectively. As
the treatment rate increases, we are able to estimate better optimal treatment rules
from larger heterogeneous samples with more information. Therefore, it is easier for
our proposed SAT-Learning to estimate the optimal regime from this more informative
sample. Thus, the simulation performance with a higher treatment rate is slightly
better than that for the lower rate case.
2.6 Application to Prostate Cancer Active Surveillance Data
We illustrate SAT-Learning using the prostate cancer Active Surveillance dataset
from Johns Hopkins University (Tosoian et al., 2011; Inoue et al., 2018; Lange et al.,
2018). In this active surveillance study, enrollment of men with low risk prostate
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Table 2.2: Simulation to mimic the monitoring and management of prostate cancer:
two intervention stages, two treatment options at each stage nested within
the exam at each stage with 500 replications, and n=1000 or 2000.
Treatment Rate 5% 15% 20% 25%
opt% opt% opt% opt%
N=1000
(a) 92.8(4.9) 93.8(4.8) 94.9(4.5) 95.3(4.6)
(b) 91.6(2.1) 93.2(1.9) 93.9(1.5) 94.3(1.4)
(c) 91.8(5.6) 93.2(5.8) 94.0(5.9) 94.6(5.5)
N=2000
(a) 93.7(4.7) 94.9(4.6) 95.7(4.4) 96.7(3.7)
(b) 92.6(1.9) 94.0(1.4) 94.5(1.2) 94.7(1.1)
(c) 92.2(6.5) 93.9(6.6) 94.6(6.5) 95.5(6.1)
a. opt% show the empirical mean and standard deviation (SD) of the percentage of subjects
correctly classified to their underlying true optimal treatments
b. The optimal regimes are estimated by the proposed method when (a) the conditional mean
model and the propensity score model are both correctly specified, (b) the conditional mean model
is mis-specified and the propensity score model is correctly specified, and (c) the conditional mean
model is correctly specified and the propensity score model is mis-specified.
c. Different treatment rates correspond to different proportions of patients who switch from active
surveillance to curative treatment among those who have taken the biopsy test.
cancer started in 1995 and ended in 2015. Eligible subjects need to have PSA density
less than 0.15 µg/L per mL, clinical stage T1c disease or lower, the Gleason score
between 2 and 6, at most 2 positive biopsy cores, and at most 50% tumor in any single
core, all of which made them low risk. The Johns Hopkins active surveillance protocol
includes semiannual PSA and annual prostate biopsy. In the protocol, the primary
reason that patients would be recommended to undergo definitive curative radiation
therapy or surgery is if the biopsy result showed an adverse change compared to
previous biopsies.
There is sufficient evidence that the approach of active surveillance, i.e. delaying
curative treatment, for low-risk patients is safe (Denton et al., 2019). The issue we
will be considering is how it should be implemented. That is, rather than having an
annual biopsy, as in the protocol, should it be more individualized, with the decision
of whether to undergo a biopsy based on the available data at that time for that
patient.
Not all the patients in the study followed the protocol. In the dataset we analyzed,
28
22% of patients did not have the scheduled biopsy of the first year and 5% of them
did not have the biopsy in the first two years. Similarly for curative therapy, quite a
number of patients did not follow the protocol. Such heterogeneity in the observed
data allows us to apply the nested DTR method via our proposed SAT-Learning to
decide at each stage whether the patient should have the biopsy, and if so, whether
the treatment should be recommended based on the patients’ individualized charac-
teristics. In the analysis presented below we restrict the observational period to be
from the diagnosis to year 4 and we make a two-year time unit for each stage, making
two stages, stage 1 being from diagnosis to year 2 and stage 2 being from year 2 to
year 4. We use D with subscript value s = 1, 2 to denote the decisions of the two
stages, and j = 1, 2 to denote the biopsy and treatment actions within the stage.
Thus, if the subject had a biopsy at the first stage, we denote D11 = 1, otherwise,
D11 = 0. For those with biopsy i.e., D11 = 1, the treatment choice is recorded as D12,
1 for treated and 0 for no treatment, and similarly for D21 and D22. We note that
once the patient is treated, no further biopsy or treatment will be observed. After the
data preprocessing, 863 patients are kept in the dataset for the analysis, and of these
230 did receive curative treatment. More information regarding data preprocessing
can be found in Appendix.
Although patients, in reality, are subject to different categories of treatments, such
as prostatectomy, radiation therapy or hormone therapy, in this analysis, we combine
all different kinds of treatments into one category (treated) to preserve a sufficient
sample size for the treated subjects. Other patient characteristics, including age,
race, baseline biopsy results, and baseline PSA were collected at the enrollment. As
the active surveillance proceeded, the corresponding PSA changes and the follow-up
biopsy results were also collected. In particular, the quantity of cancer, as measured
by biopsy results, is based on both the number of needle cores containing cancer and
the characteristic of the cancer tissue found within each single core (Gleason score).
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How the individualized data was formatted to match the two year time interval for
each stage is described in the Appendix. The reward outcome of interest was chosen to
reflect long term disease status, and is defined as the proportion of PSA values which
are less than 5 out of all the PSA observations collected from the end of year 4 after
diagnosis to the end of study. This reward ranges from 0 to 1, with the lower values
implying more undesirable risk of prostate cancer progression. This reward outcome
only considers the disease prognosis based on PSA, and ignores the potential side
effects brought by frequent biopsy and unnecessary intervention. Thus, we include
penalties to discount the patient’s reward to take into account possible side effects.
More specifically, if the patient had a biopsy in either one of the two stages, his reward
is reduced by a factor of 87% compared to the original reward. For the patient who
has ever had treatment, the reward is reduced by a factor of 80% compared to his
original reward.
To apply the proposed SAT-Learning algorithm to the active surveillance data
described above, we use random forests for the conditional mean model and a logistic
regression model for the propensity score model of every step within each stage. The
estimated optimal test and treatment DTR of the two stages are shown in Figure 2.2
According to the estimated optimal DTR, at the first stage, men older than 56 are
recommended for a biopsy test. Among those who are younger than 56 years old, the
patients with most recent PSA higher than 3.6 are also recommended for a biopsy test.
Among those doing the biopsy test, patients with the most recent PSA higher than
3.1 and having biopsy test showing any cancer are recommended for the treatment.
At the second stage, the men whose PSA change from beginning of year 2 is larger
than 1.3 are recommended for the biopsy test. For those who take the biopsy, if their
most recent PSA is higher than 3.2 or the biopsy result has more than one biopsy
core needle showing cancer positive, we recommended the physician to offer them
the treatment. The standard practice in deciding on curative treatment depends
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Figure 2.2: Estimated optimal DTR for JHU prostate cancer active surveillance data
via SAT-Learning algorithm. The trees show how to provide optimal
regime at every step based on the individualized characteristics for (A)
stage one biopsy decision, (B) stage one treatment decision if biopsy was
taken in stage one,(C) stage two biopsy decision and (D) stage two treat-
ment decision if the biopsy was taken in stage two.
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primarily on whether the Gleason grade on the biopsy is greater than or equal to
7. In contrast, the DTR we estimated involves more variables and changes from
one stage to the next, so is more individualized. It is also notable that the Gleason
thresholds in the above DTR are lower than in standard practice, which is consistent
with a suggestion in the literature (Moyer , 2012). The reward we use, long run
low PSA values, certainly does influence the estimated DTR, which involves lots of
decisions based on the current PSA values. The estimated tree-based DTR presented
in Figure 2.2 is also sensitive to the discount factor 87% and 80% which are used to
penalize the reward. Other rewards would have given different DTRs. The reward
we use of long-run PSA values can be considered as a proxy for clinical meaningful
“good” outcome. An ideal reward would have involved long term good quality of life
and absence of prostate cancer recurrence. But data to construct such a reward is not
available for this study. A sensitivity analysis with a modified reward is presented in
the Appendix.
2.7 Discussion
Motivated by the embedded nature of the diagnosis and treatment procedures, we
have developed a nested DTR framework, with the treatment decision nested within
the test decision in a multi-stage setting, and implemented the estimation of the
optimal nested DTR using a step-adjusted tree-based reinforcement learning method
(SAT-Learning). This nested DTR framework considers the test decision and the
nested treatment decision in the same stage and develops the optimal nested DTRs
to maximize the expected long-term rewards, such as disease control. This kind of
test-and-treat strategy has been considered previously in the health policy literature
(Trikalinos et al., 2009). These methods discussed the importance of the problem,
and the need to accumulate data. They also suggested solutions that focused on
the population level, but not in a rigorous mathematical framework. Our proposed
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method follows the framework of DTR, which enables physicians to repeatedly tailor
test and treatment decisions based on each individual’s time-varying health histories,
and thus provides an effective tool for the personalized management of disease over
time.
SAT-Learning, our proposed method to solve the nested step-adjusted DTR prob-
lem, can potentially be implemented via modifying other learning methods that have
been considered in DTR literature. However, by using a modified T-RL algorithm
(Tao et al., 2018), SAT-Learning is more straightforward to implement, understand
and interpret, and capable of handling various data without distributional assump-
tions. Additionally, the doubly robust AIPW estimator that we utilize in the purity
measure in the tree structure also helps improve the robustness of our method against
model mis-specifications.
Several developments and extensions can be explored in future studies. One pos-
sible exploration lies on dealing with potentially contradictory multiple outcomes.
In SAT-Learning, we consider a nested step-adjusted DTR to reduce the pain and
potential infections from frequent biopsy tests, but maintain an effective and in-time
treatment to control disease progression. If efficacy is the only purpose, one would
expect more frequent tests and more aggressive treatment regardless of possible side
effect, but in the meantime, patients might experience more side effects. The desire
for efficacy and the desire for less side effects in fact contradict each other. In clinical
practice, physicians are often interested in balancing multiple competing clinical out-
comes, such as overall survival, patient preference, quality of life and financial burden
(Butler , 2016). In order to balance these multiple potentially contradictory objec-
tives, we applied a different discount factor to the patient rewards for different side
effects in the application to the JHU Prostate Cancer Active Surveillance data. Other
statistical methods have been developed to trade-off between multiple contradictory
outcomes (Laber et al., 2014; Lizotte and Laber , 2016). One can further incorporate
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these multiple objective optimization functions into our framework of nested DTR for
future research. Another possible exploration may be considering all available actions
when the preference of multiple outcomes varies (Lizotte et al., 2012), which would
give more comprehensive information about how the optimality of an action would be
changed if the preference is modified. Sensitivity analyses can be done on the optimal
regimes and would provide further guidance for the decision maker on developing a
more flexible regime among all the available intervention strategy choices.
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for Estimating the Optimal Dynamic Treatment
Regimes
3.1 Introduction
Dose-finding has a critical role in clinical research. The optimal dose for a drug
should be balanced between the safety and efficacy requirements (Schmidt , 1988).
There has been a great deal of literature on the dose-finding methods for clinical
studies. (Braun et al., 2016; Cheung , 2011; Thall and Russell , 1998; Thall and Cook ,
2004; Thall et al., 2007; Thall , 2008). Moreover, as the interest in precision medicine
increases (Collins and Varmus , 2015), scientists realize that a one-size-fits-all optimal
dose recommendation is not appropriate for treating heterogeneous patients. Recent
dose-finding methods have also evolved to account for the patients’ characteristics
and estimate the personalized optimal dose for each individual (Li et al., 2019; Guo
and Yuan, 2017; Thall et al., 2008; Xu et al., 2018; Rich et al., 2016).
In addition to a more personalized dose assignment, treating patients with chronic
disease often includes more than one cycle of treatments. Physicians may treat pa-
tients routinely in every stage based on the current status of the time-varying biomark-
ers and other health characteristics. Typically, a sequence of decision rules should
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be considered as a whole treatment regime, rather than several independent decision
rules. This kind of sequence of treatments is not only a strategy for the management
of chronic disease, but also a device for achieving better efficacy while controlling the
toxicity (El Naqa et al., 2018). For example, patients with liver cancer were treated
at Michigan Medicine with adaptive stereotactic body radiation therapy (SBRT) with
an intra-treatment evaluation. Instead the total radiation dose at the beginning of
radiation therapy,only 60% of the total planned dose is given during the first month,
with the remaining 40% dose given or partially given after a one-month break, dur-
ing which the toxicity and the patient’s tolerability were carefully evaluated (Feng
et al., 2013). This novel adaptive treatment paradigm showed its benefit in achieving
lower toxicity while maintaining a comparable local tumor progression compared to
the non-adaptive radiation therapy (Feng et al., 2018). In this adaptive SBRT study,
there is not only one decision, but a sequence of two decision rules, one per stage,
where the second one is determined by considering the observed updated medical
characteristics after the first treatment dose. Such a paradigm is known as a dy-
namic treatment regime (DTR) (Murphy et al., 2001; Murphy , 2003; Wang et al.,
2012), which consists of decision rules, one per stage, mapping individualized patient
characteristics to a dose. However, most multiple-stage dose-finding clinical studies,
while using the individualized adaptive treatment paradigm, only evaluate the dose
response as if the patient’s outcome was due to a certain stage alone, rather than
the entire DTR (Lee et al., 2015). In addition, these studies do not take full ad-
vantage of the intra-treatment information between treatment stages (El Naqa et al.,
2018). Overlooking this dynamic treatment regime structure may result in identifying
a suboptimal dosage regime. Therefore, there is a need for a new statistical learn-
ing method that is capable of estimating the optimal dynamic dosage regime within
the setting of a DTR. In the remaining part of the article, we will refer to dynamic
treatment regimes with continuous dose treatments as dynamic dosage regime.
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Extensive statistics literature exists on estimating the optimal DTR under the
setting of multiple-stage multiple-treatment (Zhang et al., 2015; Laber and Zhao, 2015;
Tao and Wang , 2017; Schulte et al., 2014; Zhang et al., 2013). However, extending
the current methods to estimate an optimal dynamic continuous dosage regime is
not trivial. Using the observed outcomes from the patients whose dose assignment
follows a specific rule is not applicable for continuous doses, because there could be
an infinite number of treatment options for a given dose interval. Specifically, unlike
the multiple-treatment DTR problem, only a few patients may be observed using the
given dose level because that the dose level follows a continuous distribution – of which
the probability of observing a certain rule-assigned dose is zero. Thus, inadequate
methods have been developed for estimating the optimal continuous dosage regime
in a multiple-stage setting.
Analogous to the DTR problem in a multiple-treatment multiple-stage setting,
Lee et al. (2015) extended the Q-Learning (Watkins and Dayan, 1992), a commonly
used reinforcement learning method, to estimate the dynamic treatment regime for
continuous treatment. Q-Learning involves a two-step regression-based approach with
a regression model fitted in the first step. In the second step, by maximizing the ex-
pected mean outcome from the first step, the optimal treatment for a given history
can be predicted. However, Q-learning is susceptible to potential over-fitting of the
first step regression model, which may lead to a sub-optimal DTR (Lee et al., 2015).
Moreover, several modifications to outcome weighted learning (OWL) (Zhao et al.,
2012), a well-known direct method in the setting of finite treatment-option DTR, have
also been developed to accommodate the estimation of the optimal dosage regime. To
deal with the individualized treatment rule problem in an ordinal treatment setting,
Chen et al. (2018) proposed the Generalized Outcome Weighted Learning (GOWL),
which could potentially be applied for estimating the optimal dosage regime. How-
ever, the dose options dealt by GOWL remain restricted within a finite number of
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options while most dose treatment options observed in practice are on a continuum.
Chen et al. (2016) also modified the OWL for estimating a personalized optimal dose
in a continuous scale (denoted as CZK hereafter). However, analogous to its origi-
nated method, OWL, CZK is susceptible to attempting to retain the actual observed
dose, because only an observation in which the observed dose is close to the esti-
mated optimal dose can contribute to the loss function. In addition, the estimated
individualized dosage decision is affected by a simple shift of the outcome. Moreover,
the CZK and GOWL are flexible in their forms but difficult to interpret since the
dosage decisions are derived from “black boxes.” Therefore, it is more desirable to
have interpretable dosage regimes for physicians to understand and apply. Laber and
Zhao (2015) also developed a method to solve this dosage strategy problem by using a
tree-based method (denoted as LZ hereafter). LZ is capable of providing interpretable
tree-based decision rules. However, it relies on the correct specification of the outcome
regression model, and therefore LZ is fragile due to model mis-specifications.
To overcome the limitations of the existing methods, we propose a robust and in-
terpretable personalized dose-finding method, kernel-involved-dosage-decision learn-
ing (KIDD-Learning). At each stage, KIDD-Learning combines a non-parametric
estimation of the dose-response function with an interpretable tree-based decision
rule, to estimate the optimal dynamic dosage regimes in a multiple-stage setting, us-
ing observational data. The whole dynamic dosage regime is estimated by backwards
inductions.
The remaining parts of this paper are organized as follows: In section 3.2, we
formalize the problem of identifying the optimal dynamic dosage regime using the
counterfactual causal inference framework in a multiple-stage setting. Section 3.3
develops the KIDD-Learning method to solve the dose-finding problem and describes
the detailed implementation of KIDD-Learning. Section 3.4 extends the methods
to handle a time-to-event outcome to accommodate the censored data we used in
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the application section. The simulation studies and an application to the Michigan
Medicine SBRT liver cancer patient dataset are provided in section 3.5 and 3.6. A
discussion concludes this method in section 3.7.
3.2 Data and Formulation of Dynamic Dosage Regime
3.2.1 Statistical Problem for Optimizing Dynamic Dosage Regime
To address the dynamic continuous dosage regime problem above, we consider a
multiple-stage continuous dosage decision framework with T decision stages. At each
stage t, let Dt ∈ Dt denote the continuous dose value of the treatment taken at stage
t with observed value dt. Without loss of generality, we further assume Ds = [0, 1],
and dt ∈ Dt.
The patient’s accumulated history between stage t−1 and t is denoted as Xt. We
use the over bar with subscripts t to denote a vector of a variables’ history up until
stage t, i.e., Xt = (X1,X2, . . . ,Xt). Similarly, the treatment history until stage t can
be denoted as Dt = (D1, . . . , Dt−1). We use Yt to denote the intermediate outcome
at the end of stage t, and thus the overall outcome vector is (Y1, Y2, . . . , YT ) and the
outcome history Yt−1 = (Y1, . . . , Yt−1). The outcome of interest Y is a function of all
intermediate outcomes, i.e., Y = f(Y1, Y2, . . . , YT ), where f(·) is a prespecified func-
tion (e.g., sum). Y is assumed to be bounded and higher value of Y is more desirable.
The history Ht is defined as the treatment and medical history prior to treatment
decision Dt. Specifically, we denote Ht = {(Dt,Xt,Yt−1)}ni=1. The observed data
consist n i.i.d. trajectories are therefore denoted as {Dt,i,Ht,i, Yt,i}Tt=1 across patient
index i. For brevity, we suppress the subject index i in the following text when no
confusion exists. The goal of our method is to use the observed data to find the opti-
mal dosage regime that determines what dose a patient should received at each stage
based on his/her medical history. Formally, the dynamic dosage regime for the contin-
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uous treatment is defined as a personalized decision rule sequence g = (g1, g2, . . . , gT )
that maps the observed history Ht about the patient’s health characteristics to the
dose assignment at stage t, i.e.,
Ht 7→ gt(Ht) ∈ Dt, 1 ≤ t ≤ T
To identify the optimal dynamic dosage regime from the observed data, we fol-
low the counterfactual framework of causal inference proposed by Robins (1986).
Let Y ∗(g) be the counterfactual outcome if a patient follows the dynamic treatment
regime g. E{Y ∗(g)} is the expectation of the counterfactual outcome with respect
to the distribution of patients’ history if the entire population had follow the dosage
regime g. The optimal gopt is a sequence of decision rules that leads to the optimal
value of E{Y ∗(g)}, such that,
E{Y ∗(gopt)} ≥ E{Y ∗(g)}, ∀g ∈ G, (3.1)
where G is the set of all potential dosage regimes under consideration.
3.2.2 Using the Observational Data to Estimate the Optimal Dosage
Regime gopt
According to the problem described in Eqn (3.1), the expectation of counterfactual
is used to estimate the optimal dose. However, the counterfactual outcomes of sub-
jects are not available in most observational studies. Therefore, we have to apply the
framework of causal inference to connect the counterfactual outcome we desire with
the observational study data we observe. Specifically, the method to find the whole
optimal dynamic dosage regime includes backward induction; therefore, we start the
mathematical formulation from the final stage T in a reverse sequential order to the
previous treatment stages.
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At the final stage, let Y ∗(D1, D2, . . . , DT−1, dT ), or Y ∗(dT ) for brevity, be the coun-
terfactual outcome if a patient makes decision dT conditional on his/her previous his-
tories. To connect the counterfactual outcome with the observed data {DT ,HT , Y },
we make the following standard causal inference assumptions:
Assumption 1 Consistency : DT = dT implies Y = Y
∗(dT ). This assumption
ensures the observed outcome is the same as the counterfactual outcome under
the treatment actually assigned;
Assumption 2 Exchangeability : Y ∗(dT ) ⊥ DT | HT , ∀ dT ∈ DT , where ⊥
denotes statistical independence. Conditional on the previous history HT , the
counterfactual outcome under a certain dose dT is independent of the dose choice;
Assumption 3 Positivity : pi(dT | HT ) ≥ pimin > 0 for all possible HT , where
pi(dT | HT ) = ∂P (DT≤dT |HT )∂dT is the conditional treatment density given history
HT and pimin is a given positive number. It ensures that every patient has some
chance of receiving a certain treatment dT .
Under the assumptions above, we are able to identify the optimal regime using the
observed data. At the final stage T , the expectation of counterfactual outcome Y ∗(dT )
can be identified with observed data as
E{Y ∗(dT )} = E{E(Y | DT = dT ,HT )} =
∫
HT
E(Y | DT = dT ,HT = hT ) dP (hT ).
When studying the continuous exposure, especially using observational study dataset,
dose-response function is a natural way visualizing the dose-response relationship
and describing the dosage effect, rather than using a scalar (Kennedy et al., 2017).
Therefore, we denote θT (dT ) = E{Y ∗(dT )}, and θT (·) be the dose-response function of
the entire population we are interested in. To ensure the identification of the optimal
dose for the population, we further assumme:
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Assumption 4 Concavity : θT (·) is continuous on the closed interval of DT
and differentiable on the open interval of DT , and the second derivative θ′′T (·)
exists throughout the domain DT and θ′′T (dT ) < 0 ∀ dT ∈ DT . This assumption
guarantees the existence of the local maximum of the dose-response function
within the domain DT .
Let θT{gT (HT )} denote the dose-response of the outcome under regime gT . According
to Eqn (3.1), the optimal decision rule of the final stage goptT (HT ) satisfies
E[Y ∗{goptT (HT )}] ≥ E[Y ∗{gT (HT )}], ∀ gT ∈ GT ,
i.e.









For the intermediate stage t ∈ {1, 2, . . . , T − 1}, the optimal regime goptt is ex-
pressed in a reversed sequential order. It is not meaningful to compare the outcome
of the regime of the intermediate stage when the dosage regime after the current
stage are different. Therefore, we desire to compare the dosage regime of the cur-
rent stage while assuming their future dosage have been optimized. We consider
{Y ∗(D1, . . . , Dt, goptt+1, . . . , goptT )Dt=dt}, for brevity Y˜ ∗t (dt), the future optimized coun-
terfactual outcome when a patient receiving treatment dt at stage t and all future
stages dosages are under the optimal regime. Under the foregoing causal infer-
ence assumptions, the expectation of the future optimized counterfactual outcome
can be identified with observed data as E{Y˜ ∗t (dt)} = E{E(POt | Dt = dt,Ht)},
where the pseudo-outcome of stage t, POt is the calculated future optimized coun-
terfactual outcome assuming optimal regimes are followed in all the stages after
stage t. Specifically, POt can be defined recursively using Bellman’s optimality as
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POt = Eˆ{POt+1 | Dt+1 = goptt+1(Ht+1),Ht+1}, t ∈ {1, 2, . . . , T − 1} and POT = Y
for the final stage. We can similarly denote θt(dt) = E(Y˜
∗
t (dt)), and θt(·) is the
dose-response function of the entire population at stage t, and the concavity of θt(·)
should be assumed throughout the domain of Dt. Thus, this function at stage t un-





t ) ≥ θt(gt), ∀ gt ∈ Gt. In other words, the optimal regime goptt satisfies
E(Y˜ ∗t (g
opt
t (Ht))) ≥ E(Y˜ ∗t (gt(Ht))), ∀ gt ∈ Gt, i.e.,









3.3 KIDD-Learning with Tree-based Dose-search Algorithm
Given the observational data with continuous dosage, we propose solving Eqn
(3.2) and Eqn (3.3) through KIDD-Learning to estimate the optimal individualized
dynamic dose decision rule by accounting for patients’ heterogeneity.
The tree-based method has been used in personalized medicine primarily (Laber
and Zhao, 2015; Tao et al., 2018; Zhu et al., 2015) because it is the foundation of
exploratory analysis and a classical example of a model with interpretability and
predictive ability. As we also desire to obtain interpretable dosage decision rules,
the tree-based method becomes an ideal candidate. At each node of a tree-based
decision rule, the population is split into two subpopulations based on their medical
characteristics; therefore, we can assume that patients can be classified into different
sub-population based on their characteristics, and patients who fall into the same
sub-population are homogeneous in terms of response to treatment doses. Thus for a
given patient, the dose-response information can be inferred by borrowing information
from other patients in the same group.
Therefore, the optimal tree-based dosage decision rule is estimated in the fol-
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lowing steps at each treatment stage: (1) For a given split of a node, calculate the
dose-response functions of the population and the two subpopulations after split-
ting; (2) Use a tree-based dose-search algorithm to determine whether the splitting
should happen by comparing the expectation of the counterfactual dose-response out-
come of the whole population. The steps are repeated iteratively until obtaining a
reasonably satisfactory tree-based decision rule. In the first step, a non-parametric
kernel-involved regression is applied to estimate robust dose-response functions and
identify the optimal dose of the specific population. In the second step, the tree-
based dose-search algorithm, which is used to evaluate the splittings and identify the
tailoring variables, is able to yield an interpretable tree-based decision rule.
3.3.1 Estimating the Dose-response Function
For a given node, we denote ω as a subpopulation of the entire population Ω of the
parent node. For a certain stage t ∈ {1, 2, . . . , T}, we denote the causal dose-response
function for a subpopulation ω at stage t as θω,t(·) , and θω,t(dt) ,∀dt ∈ Dt, is the dose
response of the subpopulation ω when the entire subpopulation receiving dose dt. To
guarantee the optimal dose is available from θω,t(·), we further assume that θω,t(·)
should be concave throughout the domain of Dω,t. Therefore, the optimal dose of the
subpopulation ω at stage t is denoted as doptω,t = arg maxdω,t∈Dω,t θω,t(dω,t) For brevity,
we suppress ω in the remaining part of this subsection when no confusion exists.
3.3.1.1 Mapping Function for the Dose-response Function
At the final stage T , let CT ({DT ,HT , Y }) be the mapping function of the observed
data such that,
E[CT ({DT ,HT , Y }) | DT = dT ] = θT (dT ). (3.4)
Given the mapping between CT ({DT ,HT , Y }) and the dose-response function θT (dT ),
θT (dT ) can be estimated by regressing CT ({DT ,HT , Y }) on treatment dT by using the
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off-the-shelf non-parametric regression model or machine learning methods (Kennedy
et al., 2017).
At the intermediate stage t ∈ {1, 2, . . . , T − 1}, the intermediate future optimized
counterfactual outcome Y˜ ∗t (dt) is not directly available from the dataset. Therefore,
we use the pseudo outcome as defined above to replace Y in Eqn (3.4). In particular,
the mapping function before the final stage become E[Ct({Dt,Ht, POt}) | Dt = dt] =
θt(dt).Since POT = Y , we suppress the difference between the final stage T and any
intermediate stage in the following text and use E[Ct({Dt,Ht, POt}) | Dt = dt] =
θt(dt), t ∈ {1, 2, . . . , T} for all stages. The following method works for any stage
t ∈ {1, 2, . . . , T}.
The mapping function Ct({Dt,Ht, POt}) determines the quality of the estimated
dose-response function, and thus the quality of the estimated optimal decision rule.
Therefore, we consider constructing a class of mapping functions Ct({Ht, Dt, POt})
for estimating the dose-response function θt(dt). To avoid relying on the paramet-
ric assumptions or the correctly specified parametric models, we follow the semi-
parametric method for continuous treatment proposed by Kennedy et al. (2017). We
further denote that Pn is the empirical measure, pi(dt | ht) = ∂∂dtP (Dt ≤ dt | Ht = ht)
is the conditional treatment density given history and µ(ht, dt) = E(POt | Ht =
ht, Dt = dt) is the conditional mean pseudo outcome given covariates and treatment
assignment. The mapping function can be estimated by










In particular, at the final stage T , when either of µ(Ht, Dt) or pi(DT | HT ) is correctly
specified, the estimator C({DT ,HT , Y }) satisfies the property of double-robustness,
i.e., E[C({Dt,Ht, Y }) | DT = dT ] = θT (dT ). In our implementation, the conditional
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treatment density model, and the conditional mean model are fitted by the method
of random forest (Breiman, 2001).
3.3.1.2 Kernel Regression
Given such a mapping function Eqn (3.5), θt(dt) can be estimated by first esti-
mating the mapping function Ĉt(Ht, Dt, POt) and then regressing Ĉt(Ht, Dt, POt)
on treatment Dt. The construction of the regression can be done by using various
flexible methods. In this paper, we uses the local linear kernel regression.
The local linear kernel version of our estimator is θ̂h,t(dt) = gh,dt(dt)
T β̂h(dt), where
gh,dt(z) = (1, (z − dt)/h)T and
β̂h(dt) = arg min
β∈R2
Pn[Kh,dt(Dt){Ĉt(Ht, Dt, POt)− gTh,dt(Dt)β}2],
where Kh,dt(z) = K{(z − dt)/h}/h with K is a standard kernel function and h is a
scalar bandwidth parameter.
The bandwidth h is essential for the kernel regression method, because too little
smoothness may produce substantial variance while too much smoothness may yield
large bias. In KIDD-Learning, we use the data-driven cross-validation to choose
the bandwidth h for the kernel regression. Specifically, we treat the estimated
Ĉt({Dt,Ht, POt}) as known and use the leave-one-out cross-validation to select the
optimal bandwidth hopt, i.e.,










where θ̂t,h(Dt,i) is the estimated dose response for patient i when the bandwidth
equals to h, and Ŵh(Dt,i) = (1, 0)Pn{ghdt(dt)Kh,dt,i(Dt)gh,dt(dt)T}−1(1, 0)Th−1K(0) is
the ith diagonal of the hat matrix. We expect that this approach of selecting optimal
bandwidth hopt is asymptotically equivalent to using the oracle bandwidth selector
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(Kennedy et al., 2017).
3.3.2 Tree-based Dose-search Algorithm for KIDD-Learning
The algorithm of dose search is a modified method of the tree-based reinforcement
learning method (Laber and Zhao, 2015), which uses the classification and regression
tree (CART) proposed by Breiman et al. (1984). CART explores the relationship
between the directly observed or given classification label and the covariates, and
then builds a decision tree with the purest child nodes, which means having the
lowest mis-classification rate among all possible splits. In this dose-search problem,
the optimal dose, i.e., the label, is unknown and only available indirectly through the
counterfactual outcome. Therefore, to make use of this indirect information, we use
the expected counterfactual outcome as the purity measure, and build the tree-based
decision rules by maximizing the expected counterfactual outcome. Since the tree-
based dose-search algorithm of KIDD-learning involves infinite dose options within
the given dose range, the purity measure should be modified accordingly using the
estimation the dose-response function.
3.3.3 Implementation of KIDD-Learning
3.3.3.1 Purity Measure
A measure of node purity is used to facilitate the recursive splitting procedures
when growing a decision tree. For a given partition ω and ωc of a node Ω, we evaluate
the dose-response function separately for Ht ∈ ω as θω,t(dω,t) and for Ht ∈ ωc as
θωc,t(dωc,t). We first define the purity measure of stage t as
Pt(Ω, ω) = θ̂ω,t(dω,t)Pn[I(Ht ∈ ω)] + θ̂ωc,t(dωc,t)Pn[I(Ht ∈ ωc)],
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where Pn is the empirical expectation operator. Under the causal assumptions,
θ̂ω,t(dω,t) is the estimator of the expected dose response of subpopulation ω if all
the subjects in ω takes dose dω,t. However, comparing the purity by enumerating
all possible dω,t and dωc,t is not efficient to find the best partition. Instead, we first
maximize each partition’s purity by plugging in the optimal dose of each partition
ω and ωc, and then accept the partition with the highest purity as ωopt. Based on
the assumption of the concavity of the dose-response function, for a given partition
ω and ωc, the purity measure can be re-written as
Pt(Ω, ω) = θ̂ω,t(doptω,t)Pn[I(Ht ∈ ω)] + θ̂ωc,t(doptωc,t)Pn[I(Ht ∈ ωc)], (3.6)
where doptω,t = arg maxdω,t∈Dω,t θ̂ω,t(dω,t) and d
opt
ωc,t = arg maxdωc,t∈Dωc,t θ̂ωc,t(dωc,t).
3.3.3.2 Recursive Partitioning
When maximizing the purity measure Pt(Ω, ω) as Eqn (3.6), a split ω can be
either a category level of a categorical covariate or values of continuous covariates that
are not larger than the threshold. The best partition ωopt, which leads to the dose
assignments doptω,t and d
opt
ωc,t , should maximize the improvement of Pt(Ω− ω)−Pt(Ω),
where Pt(Ω) means no splitting; i.e., all the subjects in Ω are assigned the same dose.
It is obvious that Pt(Ω− ω)− Pt(Ω) ≥ 0. To provide a practically meaningful split,
the improvement of purity should exceed a positive threshold λ . In addition, to avoid
overfitting and prune a feasible decision tree, we define the minimal node size n0, the
minimum number of subjects of a terminal node, and depthmax, the maximal number
of edges from the node to a tree’s top root node. If n0 is too small or depthmax is too
large, we will end up with an overfitted, overly precise dosage decision rule. Given
the hyper-parameters, λ, depthmax and n0, the following Algorithm 2 is implemented
as the stopping rules to split each node and stop while the rules are violated. Note
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here, nΩ is the total number of subjects in the parent node Ω.
Algorithm 2 Stopping Rules
if the current tree depth reaches the pre-specified depthmax then
Do not split the node
else
Calculate the best split by
ω̂opt = argmax
ω
[Pt(Ω, ω) : min{nΩPnI(Ht ∈ ω), nΩPnI(Ht ∈ ωc)} ≥ n0] .
if the maximum purity improvement Pt(Ω, ω̂opt)− Pt(Ω) < λ then
Do not split the node
else





KIDD-Learning is implemented by a backward induction in a reversed sequential
order. At each stage, the optimal dosage decision is made by recursively evaluating
the dose-response function θt(dt) of each stage. Before determining the dose-response
function of each stage t, we have to calculate the pseudo outcome POt, which is
the replacement of the outcome Y in the intermediate stages. At the final stage
t = T , POT = Y , and thus POT can be used directly from the observed outcome.
In the stage t ∈ {1, . . . , T − 1}, the pseudo-outcome POt requires that the estimated
dosage decision rules of the future stages have been already optimized, as POt =
Eˆ{POt+1 | Dt+1 = goptt+1(Ht+1),Ht+1}. We further assume the dosage effect of the
intermediate outcome Yt is cumulatively carried forward to the final outcome Y . To
reduce the accumulated bias of each stage, we calculate the pseudo outcome POt by
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using actual observed outcomes at stage t, plus the predicted pseudo outcome gain
due to the optimized future dose assignment of the stages after t (Huang et al., 2015);
that is
POt = Y +
T∑
j=t+1
{E(POj | Hj, Dj = goptj (Hj))− E(POj | Hj, Dj = dj)},
where POT = Y and the conditional outcome of POt is calculated by using the off-
shelf machine-learning method “eXtreme Gradient Boosting” (Chen and Guestrin,
2016). In practice, the intermediate outcomes Yt can be different measures of a
patient’s disease status, such as toxicity or efficacy, due to different priorities of treat-
ment during the progression of the disease. Therefore, we should standardize the scale
of different intermediate measurements before aggregating them from different stages
into the final outcome. In some particular stage where the intermediate outcome
cannot be directly observed but the effect of the outcome is carried forward, we can
specify these outcomes as zero. The implementation of KIDD-Learning is outlined in
Algorithm 3, where m ∈ {1, 2, . . . , 2depthmax − 1} is the index of the node.
3.4 Extension to Survival Outcome
A time-to-event outcome, such as overall survival or local progression, is com-
monly used in oncology studies to evaluate the treatment performance. However, a
patient may have been censored from the study before the event happens, and the
observed censored time for the patient cannot be directly used as a continuous out-
come. Therefore, we extend the proposed method from using continuous outcomes
to using survival outcomes, following the recursive imputed survival time (RIST)
method proposed by Zhu and Kosorok (2012). We modify RIST to transform the
actual censored time into the expected conditional survival time, and then use it as
a continuous outcome for KIDD-Learning.
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Algorithm 3 Implementation of KIDD-Learning
Result: gopt = gopt1 , . . . , g
opt
T
Set t = T and POT = Y
while t ≥ 1 do
Set m = 1 at root node Ωt,m
while m ≤ 2depthmax − 1 do
Use subjects with history Ht ∈ Ωt,m
if Stop at the Stopping rules at node Ωt,m then
Assign a single best treatment doptt = arg maxdt∈Dt θt,Ωt,m(dt) to all subject
in Ωt,m
else
Split Ωt,m into child nodes Ωt,2m and Ωt,2m+1 by ω̂
opt
end if
m = m+ 1
end while
t = t− 1
Set POt = Y +
∑T
j=t+1{E(POj | Hj, Dj = goptj (Hj))− E(POj | Hj, Dj = dj)},
end while
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For brevity, we suppress the stage subscript t in the following derivation when no
confusion exists. Let Ti be the event (death) time for of the i
th patient, let Ci be
the censoring time for the ith patient, and let δi = I(Ti ≤ Ci) be the non-censoring
indicator, 1 as event (death) and 0 as censored. We further define the observed
survival time Ri = min(Ti, Ci), and let Xi be the patient’s history and Di be the dose
assignment of the patient i. The observed data consist n i.i.d. {Ri, δi, Xi, Di}ni=1.
Since the event time is not always observed, we use a replacement of the observed
event time while maintaining a similar outcome. Therefore, we denote Yi as the
outcome, which is defined as the expectation of survival time Ti conditional on the
covariates Xi, and Di, censoring status δi and the observed survival time Ri. We
further assume that the censoring is independent of the survival time conditional on
the covariates (Cui et al., 2017). We also assume that there is a maximum length of
follow-up time τ . Since the survival time of event patients, i.e., δi = 1, is known, we
focus on estimating the conditional expectation of T which is truncated at τ as,
Yi = E(Ti | Xi, Di, Ri, δ)
= I(δi = 1)Ri + I(δi = 0)E(Ti | Xi, Di, Ti > Ri)
Next, we can calculate the conditional survival time for the censored patients by
taking the integral of the conditional survival function, and the conditional survival
function can be estimated by fitting survival decision trees (Ishwaran and Lu, 2019).
To have a more stable conditional survival function, we repeat the survival tree
splitting for K times and then average over all K trees. For each terminal node in
kth tree, we calculate a Kaplan-Meier estimate of the survival function within each
node, which is denoted by Ŝk(t). Every patient will only fall into one terminal node
for each fitted decision tree. Therefore, we denote the single-tree survival function
by Ŝik for the i







k(t). Given a subject i who is censored at time Ri, we can
52
approximate the conditional probability of survival, Pr(Ti > t | Xi, Di, Ti > Ri, ), by
Pr(Ti > t | Xi, Di, Ti > Ri, ) =

1 if t ∈ [0, Ri]
Ŝi(t)/Ŝi(Ri) if t ∈ (Ri, τ ],
where τ is the pre-specified maximal length of follow-up time of the study.
3.5 Simulation Studies
We conduct simulation studies to investigate the performance of KIDD-Learning
under different scenarios. At first, to facilitate the comparison with existing methods,
in particular CZK (Chen et al., 2016), Q-learning regression-based SVR, and LZ
(Laber and Zhao, 2015), we consider single-stage scenarios and two-stage scenarios.
For each scenario, we consider sample sizes of 500, 800 or 1000 for the training dataset
and evaluate the performance on a test dataset with a sample size N=1000, and
replicate them 500 times.
The training datasets are used to estimate the optimal dosage regime and then
predict the optimal dosage decision in a separate test dataset, where the underlying
true optimal dosage regime is already known. The opt% shows the average pro-
portion of subjects correctly classified to their true optimal dose according to the
estimated optimal dosage regime. The expectation of the estimated counterfactual
dose-response outcome Ê(Y ∗(ĝopt)), i.e., the expected dose response under the esti-
mated dosage regime ĝopt, is also used to evaluate the performance. This expected
value is calculated by plugging the estimated optimal dose into the true pre-specified
underlying value function. Since the results of opt% and Ê(Y ∗(ĝopt)) are not normally
distributed (Tao et al., 2018), the results shown in Table 3.1 and 3.2 are medians and
the interquartile range from 25th quartile to 75th quartile.
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3.5.1 Single-Stage Scenarios
We consider a single-stage case with a continuous dose and implement KIDD-
Learning in the training dataset, of which the sample size is 500, 800 or 1000. We first
generate three baseline covariates X1, X2, X3 according to N(0, 1). The treatment
D1 is set within the range of D1 = [0, 1], and we generate it from Beta(α, 1−α) with
α = 1/{1 + exp(0.3X1 + 0.2X2 + 0.1X3)}, which makes D1 depend on the observed
covariates.
The continuous outcome Y1 has the form of Y1 = m(D1)+βH1+1, where βH1 =
0.5X1 + 0.3X2 + 0.7X3 and 1 is an independent standard normal variate that follows
N(0, 1). In addition, m(d1) ∝ I(gopt1 = 0.5)F24,24(d1) + I(gopt1 = 0.2)F6.75,24(d1) +
I(gopt1 = 0.8)F24,6.75(d1), where Fp,q(d1) is a unimodal function within the domain




q−1Γ(p+ q)/{Γ(p)Γ(q)} is the probability density function of Beta(p, q).
We consider two forms of the underlying optimal dosage assignment, one is a
tree-type dosage regime and the other one is a non-tree-type regime, to study the
impact of underlying model specification has on the performance of KIDD-Learning.
The underlying tree-type is consistent with the dosage assignment model when using
the proposed tree-based dose-search algorithm, while the underlying model is “mis-
specified” for the non-tree-type regime. In particular, the underlying optimal dose
for the tree-type dosage regime is specified as gopt1 (H1) = 0.8I(X1 > 0.4) + 0.2I(X1 ≤
0.4)I(X2 ≤ 0) + 0.5I(X1 ≤ 0.4)I(X2 > 0). The optimal dosage regime for the non
tree-type is specified as gopt1 (H1) = 0.8I(X1 +X2 > 0.6)+0.2I(X1 +X2 ≤ 0.6)I(X2 ≤
−0.3) + 0.5I(X1 +X2 ≤ 0.6)I(X2 > −0.3).
For comparison, three methods, CZK, SVR, and LZ, are considered. CZK, pro-
posed by Chen et al. (2016), is a non-linear version of the modified outcome weighted
learning method to estimate the individualized dosage regime, a special case of DTR.
It uses a non-convex loss function for optimization and provides a difference of convex
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functions to solve the optimization problem. SVR includes a two-step procedure sim-
ilar to Q-learning: in the first step, the non-linear relationship between the outcomes
and the dosage decision, and relationship between covariates and dose are evaluated
by a Gaussian kernel. The parameters of SVR are tuned by five-fold cross-validation.
In the second step, since the closed-form expression of the optimal dosage regime is
not available, we choose 200 equally distributed grids within the dose interval (0, 1)
and find the optimal dose, and thus the optimal dosage regime. In addition, we use
the a non-parametric method for CZK and SVR, as presented in Chen et al. (2016),
to estimate the density of having a certain dose conditional on the covariates. LZ is
another tree-based reinforcement learning method that uses CART to estimate the
optimal DTR for continuous dose. Comparing with KIDD-Learning, LZ calculates
the purity measure by using the kernel density and evaluates the purities of given
doses to yield the optimal dosage regime. These comparison are implemented using
R packages “kernlab” (Karatzoglou et al., 2018), “SVMW” (Chen et al., 2016) and
“np” (Hayfield and Racine, 2008).
Table 3.1 summarizes the result for the single stage scenario. It shows that KIDD-
Learning outperforms CZK, SVR and LZ in all settings. Specifically, when sample size
N=1000, KIDD-Learning correctly estimates 97.3% subjects into their optimal dosage
regime, and the median of the estimated estimated mean counterfactual outcome
is 9.72, which is very close to the pre-specified true value 10. When the sample
size decreases, the performance of KIDD-Learning decreases as expected. When the
sample size N=500, the performance decreases but is still superior to CZK, SVR
and LZ with the median of the estimated counterfactual outcome equals 9.06 with
90.65% of the subjects correctly classified. CZK uses more information from the
observations who have higher observed outcome; if the received doses of a large part
of the population are close to their optimal doses, the performance of CZK should be
satisfactory. However, it is not the case in our simulation study and not common in
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the observational study either. Therefore, the compromised performance of CZK is
to be expected (Chen et al., 2016).
We further consider a setting that mimics a situation when the tailoring variables
that interact with the dose assignment are not clear to the researchers. Specifically, it
is a setting with 7 additional baseline variables,X4, . . . X10, simulated independently
from N(0, 1), and the outcome Y1 = m(D1) + βH1 + 1, follows the previous setting,
where βH1 = 0.5X1 + 0.3X2 + 0.7X3 +
∑10
i=4 0.2Xi. In this setting, we intend to
see how the noise interference may affect the performance of the four methods under
different sample sizes and different underlying optimal dosage regimes.
The results of simulation study including more noise baseline covariates are shown
in Table 3.2. In general, KIDD-Learning has the highest performance of the methods
compared. Although all methods in all cases have worse performance than the results
shown in Table 3.1, the regression-based SVR is the most sensitive to the increase
of the dimension of noise covariates. When the sample size is 1000 and under the
pre-specified tree-type dynamic dosage regime, the median of estimated expectation
of counterfactual outcome E{Y ∗(ĝopt)} of SVR is 3.10, which is almost half of that
in the case with fewer noise variables. Compared with Table 3.1, KIDD-Learning has
a decreased performance in opt% and Ê(Y ∗(ĝopt)) in general, but the performance
is still reasonably satisfactory when we have a sufficient sample size, i.e., N=1000
or N=800. Specifically, the median of expectation of counterfactual outcome when
N=1000 is 9.60, and opt% is 96.2%, which is only decreased by 1% from its counterpart
in Table 3.1. In general, the performance gets worse when the sample size decreases,























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































To mimic the multiple-stage dynamic dosage regime, data under a two-stage con-
tinuous dynamic dosage regime are generated and evaluated at sample sizes of 500,
800 or 1000. The outcome we are interested in is the sum of the intermediate out-
comes of each stage, i.e., Y = Y1 + Y2. Similar as the single stage scenarios, we also
consider the underlying true optimal dosage regime as tree-type or non tree-type.
To help make decisions in the second stage, we generate two time-varying biomark-
ers X4 and X5, in addition to three baseline covariates X1, X2, X3 as the setting of
the single-stage scenario; X1, X2, . . . , X5 are simulated independently from N(0, 1).
For the first stage, we generate D1 from Beta(α, 1−α) with α = 1/{1 + exp(0.3X1 +
0.2X2 + 0.1X3)}. The continuous outcome of the first stage Y1 has the form as
Y1 = m1(D1) + βH1 + 1, where βH1 = 0.5X1 + 0.3X2 + 0.7X3 and m1(d1) ∝
I(gopt1 = 0.5)F24,24(d1) + I(g
opt
1 = 0.2)F6.75,24(d1) + I(g
opt
1 = 0.8)F24,6.75(d1). We
also assume the independent standard normal variate 1 ∼ N(0, 1). Specifically,
the underlying optimal dosage regime of stage 1 for the tree-type dosage regime is
specified as gopt1 (H1) = 0.8I(X1 > 0.4) + 0.2I(X1 ≤ 0.4)I(X2 ≤ 0) + 0.5I(X1 ≤
0.4)I(X2 > 0). The optimal dosage regime for the non tree-type is specified as
gopt1 (H1) = 0.8I(X1 +X2 > 0.6)+0.2I(X1 +X2 ≤ 0.6)I(X2 ≤ −0.3)+0.5I(X1 +X2 ≤
0.6)I(X2 > −0.3). At the second stage, the treatment assignment D2 is also generated
from Beta(α, 1−α) with α = 1/{1+exp(0.3X5+0.2X5+0.1X3)}. The continuous out-
come Y2 = m2(D2)+βH2+2, where βH2 = 0.3X1+0.2X2+0.5X3+0.6X4+0.2X5 and
m2(d2) ∝ I(gopt2 = 0.5)F24,24(d2) + I(gopt2 = 0.2)F6.75,24(d2) + I(gopt2 = 0.8)F24,6.75(d1).
Again, we assume 2 ∼ N(0, 1). The underlying optimal dosage regime of stage 2
for the tree-type dosage regime is specified as gopt2 (H2) = 0.8I(Y1 > 1) + 0.2I(Y1 ≤
1)I(X4 ≤ −0.1) + 0.5I(Y1 ≤ 1)I(X4 > −0.1). The optimal dosage regime for the non
tree-type is specified as gopt1 (H1) = 0.8I(Y1 +X5 > 1.3) + 0.2I(Y1 +X5 ≤ 1.3)I(X4 ≤
0) + 0.5I(Y1 +X5 ≤ 1.3)I(X4 > 0)
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Since the performances of CZK from the single-stage scenarios is consistently infe-
rior to other methods, we only modify the regression-based SVR and LZ for compar-
ison in the two-stage scenario. Specifically, to use SVR in this two-stage scenario, we
apply the multiple-stage Q-learning and use support vector regression as the regres-
sion model. The search for optimal dosage regime is similar to that of the single-stage
scenarios.
Results for different sample sizes and underlying optimal dosage regimes are shown
in Table 3.3. Given a tree-type underlying dynamic dosage regime with a sample size
N=1000, the median of the estimated mean counterfactual outcome of KIDD-Learning
is 19.56, which is fairly close to the optimal value of 20. For both stages, 96.0% of the
patients are correctly assigned to their optimal dosage regime, with 96.4% for stage 1
and 99.9% for stage 2. In contrast, SVR only has 7.81 in the median of the estimated
mean counterfactual outcome, and the opt% is only 9.6% for both stages, and LZ is
better than SVR with Ê(Y ∗(ĝopt)) = 14.77 and opt%=22.25%. A similar superiority
of KIDD-Learning is also found under different types of underlying dynamic dosage
regimes and different sample sizes. Moreover, when the sample size decreases, the
performance of all methods is compromised. Specifically, the convergence rate of
the dose-response function using kernel regression is much slower than that of the
parametric case; therefore, the relatively worse performance with a smaller sample
size is to be expected. In particular, when the underlying true dynamic dosage regime
is correctly specified, i.e., under the tree-type setting, the performance of KIDD-
Learning with sample size N=500 is still reasonably satisfactory, with Ê(Y ∗(ĝopt)) =






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































3.6 Application to Liver Cancer Adaptive Stereotactic Body
Radiation Therapy Data from Michigan Medicine
In radiation therapy, higher doses of radiation therapy (RT) are often associated
with improved tumor control but also increased risk of toxicity. At the same time,
by splitting the treatment into multiple stages, with a break in between, the radiated
normal cells may recover better from the treatment and reduce the risk of toxicity
(Jackson et al., 2019). Thus, selection of the optimal dose requires a tradeoff be-
tween efficacy and toxicity when planning the optimal treatment dosage, accounting
for individual patient characteristics. Patients vary in terms of their sensitivity to
radiation therapy (Lawrence et al., 1995), so splitting an RT plan into two stages
provides the opportunity to identify the more sensitive patients based on early mea-
sures following the first stage of treatment. However, to our knowledge, there are
no existing applications of a dynamic treatment regime framework in the setting of
radiation oncology.
We apply the proposed KIDD-Learning method to a Michigan Medicine liver
cancer dataset comprised of several clinical trials using adaptive SBRT (Feng et al.,
2018, 2013). In these studies, patients were treated with an initial RT plan followed by
an assessment of liver function after a one-month break. After the treatment break,
additional doses were given depending upon the change in measures of liver function.
The dataset we used consisted of 202 patients treated with a range of doses during
stage 1 due to physician preference, tumor size and tumor location. 84 patients
stopped RT after stage 1 with no further dose, 21 patients received a lower than
planned dose for the second stage, and 97 continued with the planned dose for the
second stage. Such heterogeneity of treatment allowed us to apply KIDD-Learning
to estimate a optimal personalized dosage regime; in other words, we consider what
dose should be given for patients for the first stage using baseline covariates and what
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is the optimal radiation dose for the second stage, using both baseline covariates and
updated covariates observed after stage 1.
Patients’ RT tumor dose ranged from 29 Gy to 119 Gy for the first stage, and from
0 Gy (no further RT) to 71 Gy for the second stage. Patients’ baseline characteristics,
including age, gender, cancer history, tumor size, gross tumor volume, mean liver
dose, and other biomarkers (ALBI raw score, Child-Pugh score, ECOG.PS score,
AST, ALT and Alkphos), were collected. The key concept underlying the two-stage
dosage regime is that the full planned course of treatment may be too toxic for some
patients. Thus the plan was to give 60% of the total planned dose during stage 1
and then, based on the resulting change in liver function, possibly give an additional
dose, but no greater than initially planned. Exactly how the stage 2 dose was selected
varied across patients.
To consider the trade-off between efficacy and toxicity, overall survival becomes
an appropriate outcome to be maximized when estimating the optimal dosage regime,
because severe toxicity damages the normal liver function, which then impacts the
long-term life expectancy; on the other hand, better efficacy on the cancer cells avoids
patients suffering from cancer progression, leading to a longer and better life. Overall
survival also matches our method as we assume higher outcome values are preferable.
In particular, when using the overall survival as the final outcome, we are assuming
all intermediate outcomes as zero and only the overall survival after the final stage
can be used as the final outcome. We use the RIST (Zhu and Kosorok , 2012) as
described in section 3.4 to impute the conditional survival time for the patients who
were censored from the study before their death. This conditional time is truncated
at 3821 days, which is the longest observing time of this adaptive SBRT study.
The estimated optimal dosage regime of this two-stage adaptive SBRT is shown in
Figure 3.1. In particular, after consulting with radiologists, the dose recommendation
of the estimated optimal regime is one of the pre-specified candidate dose levels that
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uses 10-quantiles from the observed dose, instead of an overly precise dose on a
continuum. According to the estimated optimal dosage regime, at the first treatment
stage, patients whose ALT baseline was larger than 58 should be given 29 Gy. Patients
whose ALT baseline was larger than 50 but less than 58 were recommended for 55 Gy
at the first stage. This splitting rule that gives patients with a worse baseline liver
condition a lower dose has been suggested in the literature (Lawrence et al., 1995).
Moreover, for patients with ALT baseline less than 50, but AST baseline larger than
39, 55 Gy should also be given. For the remaining patients with lower ALT (<50)
and lower AST (<39), their dose recommendations were based on their tumor size;
i.e., a larger tumor size would be given 84 Gy while a smaller tumor size would be
given 119 Gy. At the second stage, in addition to the baseline risk factors, we also
included the ALBI change from the baseline as a covariate. The estimated optimal
dosage regime shows that, for patients with a lower planned dose of the first stage
(<78 Gy), 55 Gy should be given. For patients with a higher planned dose (>78 Gy),
the patients with larger ALBI change should be given a lower dose (25 Gy), and vice
versa (44 Gy with smaller ALBI change).
Our recommendation that giving patients with a larger ALBI change a lower
second stage dose is consistent with what has been reported in the literature, including
that mid-treatment ALBI change in the analysis improved the ability to predict the
liver toxicity (Jackson et al., 2019) and greater mid-treatment increases in ALBI
were associated with decreased overall survival (Morris et al., 2019). ALBI is also
recommended in practice since it is easily obtained from standard lab tests and is
more sensitive than other commonly used biomarkers (Mohammadi et al., 2018). Our
results revealed some potential predictive biomarkers on which the optimal dosage
regime should depend, such as AST and ALT at baseline and ALBI change at the
second treatment stage. These results give radiologists a way to design randomized
dose-response studies in the future to confirm the findings and to better treat patients.
64
Figure 3.1: The estimated optimal dosage regime for patients with liver cancer from
Michigan Medicine adaptive stereotactic body radiation therapy dataset
In addition to the consistent findings with clinical experience, the patients from
this study would benefit from our estimated regimes by increasing their overall sur-
vival time when receiving the estimated optimal dosage regime. According to our
model, the mean overall survival (in days) of the population would increase from 997
to 2190 days after utilizing the estimated optimal dosage regime at both treatment
stages.
3.7 Discussion
To overcome the limitations of current methods when dealing with the dose-finding
problem within the framework of a dynamic dosage regime, we developed the KIDD-
Learning to estimate the personalized optimal dosage regime by accommodating pa-
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tients’ time-varying medical characteristics. The results from simulation studies have
shown that KIDD-Learning has consistently superior performance compared to ex-
isting methods, in terms of maximizing the expect ed counterfactual outcomes and
correctly assigning the optimal dosage regimes. Unlike other flexible dosage rules
assignment methods (Chen et al., 2016, 2018), the tree-based decision rules are eas-
ily interpreted and implemented. In particular, with the estimated decision rule,
when a patient is newly presented at a clinic, a physician can easily determine the
recommended dose for this patient based on his/her characteristics without addi-
tional calculation. Compared with LZ, a method also yields tree-based decision rules,
KIDD-Learning is more robust under different scenarios when using observational
data.
We also illustrate the potential application of KIDD-Learning to a Michigan
Medicine liver cancer SBRT dataset. The dosage decision for each stage of a multiple-
stage adaptive radiation therapy is currently more experience-based rather than based
on evidence-based, quantitative tools, with no previous statistical methods to handle
such a problem. KIDD-Learning uses a kernel-involved decision learning approach to
estimate the optimal dosage strategy backwards from the second stage; therefore, the
optimal dose assignment for the first stage is determined conditional on the already
optimized outcome of the second stages. In this way, KIDD-Learning is an effective
tool for physicians to provide optimal personalized radiation therapy over time.
There are a few directions for future work. One possible direction concerns the
limitation of the dose-search algorithm we used to estimate the tree-based decision
rule of each treatment stage. This tree-based dose-search algorithm, which splits the
nodes from the top root node to terminal nodes, is based on a greedy algorithm, be-
cause the optimal decisions are made at each node without looking ahead to further
child nodes. If there are strong predictors hidden from relatively weak imperceptible
nodes, this top-down greedy algorithm may fail to find the optimal splitting rules
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and fall into some sub-optimal rules. One way potentially to eliminate this greedi-
ness is “lookahead” (Murthy and Salzberg , 1995) by evaluating the future child nodes
before splitting on their parent node. We tried “lookahead” in our preliminary simula-
tion studies; the improvement of performance was moderate while the computational
time increased substantially. To reduce the potential local optimality brought by the
greedy top-down algorithm, some alternative search methods have been developed
in computer science literature, such as stochastic tree search using the methods of
Markov chain Monte Carlo (Denison et al., 1998; Chipman et al., 1998; Wu et al.,
2007; Wang et al., 2017) and evolutionary algorithm (Papagelis and Kalles , 2001).
In a future study, we will improve KIDD-Learning by incorporating these alternative
search methods and providing more robust optimal decision rules.
Another possible exploration would address the potentially competing outcomes
for determining the optimal dosage regime, such as efficacy, toxicity, side-effects and
cost burden. In the data illustration of Michigan Medicine Liver SBRT dataset,
we consider the overall survival as the outcome, as it is a combination of treatment
effectiveness and toxicity. However, when a composite outcome, like overall survival, is
not available, a method that is capable of balancing multiple contradictory objectives
is desirable (Butler et al., 2017). Some statistical methods have been developed
to compromise between multiple contradictory outcomes (Lizotte and Laber , 2016;
Wang et al., 2019), but none is able to estimate the optimal dose on a continuum
within the framework of dynamic dosage regime. One potential future direction is to




Stochastic Spline-Involved Tree Search for
Optimizing Personalized Multi-stage Dosing
Strategy
4.1 Introduction
Determining the optimal dosage is of paramount importance in drug development
and personalized medicine (Schmidt , 1988; Thall et al., 2007; Thall , 2008; Guo and
Yuan, 2017; Xu et al., 2018). An optimal treatment dose usually balances effectiveness
and side-effects. Increasing the drug dose can intensify the treatment effect at the cost
of damaging the function of normal organs, while a low drug dose may result in a lack
of efficacy. Moreover, as the interest in precision medicine has emerged (Collins and
Varmus , 2015), scientists are more interested in providing individualized doses for
patients with heterogeneity, rather than giving a one-size-fits-all optimal treatment
recommendation. Recently, statistical methods have been developed to accommodate
the need for estimating the personalized optimal dose for each individual (Li et al.,
2019; Guo and Yuan, 2017; Thall et al., 2008; Xu et al., 2018; Rich et al., 2016).
Moreover, when treating chronic diseases, such as cancer or diabetes, clinical de-
cision making often involves the determination of overall dose level and the allocation
of drug doses over several treatment stages. Doctors routinely provide treatments
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based on patients’ baseline covariates and time-varying characteristics. For exam-
ple, in treating patients with diabetes, insulin dose titration has become a common
practice to balance the desired sufficient insulin effectiveness and a patient’s toler-
ance of vomiting and nausea (Scarpello, 2001; Qu et al., 2019). Dose titration allows
patients to start from a low insulin dose and gradually escalate to higher dose levels
according to their tolerance to the drug. Such a treating process involves a sequence
of dose assignments chosen based on up-to-date patient information. This kind of
idea of personalizing treatment decisions over time has been formalized as the Dy-
namic Treatment Regimes (DTRs) (Murphy et al., 2001; Wang et al., 2012). DTRs
generalize the individualized medical decisions into a time-varying treatment setting
and thus accommodate the updated information for each person at each stage. In
the remaining part of this article, we will refer to dynamic treatment regimes with
continuous dose treatments as dynamic dosage regimes.
There has been a rapidly growing literature in estimating the optimal multiple-
stage DTR with binary treatment or finite multiple treatments (Zhang et al., 2015;
Laber and Zhao, 2015; Chen et al., 2018). However, it is complex to extend existing
methods to personalized dose-finding because of the sparse nature of the observed
data, i.e., the dose level follows a continuous distribution – of which the probability
of observing any specific dose is zero. Estimating the optimal DTR for continuous
treatment has received less attention in the literature; some examples include Lee
et al. (2015); Chen et al. (2016, 2018); Schulz and Moodie (2020). However, many
of these methods have limited interpretability, which hinders their potential impact.
Laber and Zhao (2015) (denoted as LZ hereafter) proposed a tree-based method for
estimating optimal DTR with continuous treatments, and demonstrated the promis-
ing performance under various scenarios. However, these methods require specifying
the parametric working model for the treatment assignment mechanism, or the con-
ditional outcome, or both. The quality of estimated DTRs is tied to how adequately
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the working models approximate the true data-generating mechanism. In practice, it
is difficult to correctly specify the outcome regression model even with background
knowledge of the observed population.
In Chapter III, KIDD-Learning and implemented it using a modified tree-based
reinforcement learning method. KIDD-Learning can estimate the optimal tree-based
dosage regime. However, when implementing KIDD-Learning, the tree-based decision
rules are constructed using a modified Classification and Regression Tree (CART)
dose search algorithm. In CART, as the decision tree grows from the root node,
a split is determined when the expected counterfactual outcome increases, and the
splitting process stops after reaching the prespecified stopping criteria. However, the
CART dose search algorithm is limited by its greedy nature, because splits are myopic
and may fail to account for the possible impact of future partitions. Such a top-down
algorithm generates a sequence of trees, each of which is a direct extension of the
previous decision tree, and inevitably results in a locally optimal tree if the previous
tree is already sub-optimal.
In addition, most of the existing methods listed above limit their application to
data from randomized dose trials, where the confounders have been well-adjusted.
Real world observational data are more common, because of the cost and the ethical
concerns (Wallace et al., 2018). Applying the methods designed for randomized trials
directly without carefully adjusting for confounders may lead to a sub-optimal dosage
regime. Specifically, in the method developed by Chen et al. (2016) (denoted as CZK
hereafter), it was claimed that CZK remained valid by using an inverse weight of the
density model conditional on the covariates from the observed data. However, their
simulation results showed that the performance of CZK did not change much with or
without adjusting for confounders. CZK’s potential extension to using observational
data thus needs further exploration and validation.
Therefore, a robust and interpretable method for estimating the optimal dynamic
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dosage regime using observational data is highly desirable, as it bridges the gap be-
tween the clinician’s medical expertise and data-driven dosage regimes, and allows a
clinician to better understand and trust the regimes. In this article, we propose a
stochastic spline-involved tree search learning method, SSITS for estimating the op-
timal dosage regime, which is an extension of KIDD-Learning. This new method
combines a robust non-parametric estimation of the dose-response function with
an efficient simulated annealing tree search algorithm for estimating interpretable
dose decision rules over multiple decision stages. At each treatment stage, our pro-
posed method stochastically searches the binary decision tree space and then pro-
vides the optimal decision rule by comparing the maximum value of each estimated
dose-response function. Compared to its CART counterpart, SSITS can search the
tree space more efficiently and is more capable of escaping the local optimality. In
the cases of multiple-stage multiple-treatment DTR, the effectiveness of the stochas-
tic search has been demonstrated by Sun (2019). Similar superiority is expected in
SSITS when estimating the continuous dose DTR. In addition, unlike KIDD-Learning
where the dose-response function has to be fitted to evaluate every possible splitting,
this proposed method only fits the non-parametric regression model in the resulting
terminal nodes for each visited tree and therefore is more computationally efficient
than KIDD-Learning.
This article is organized as follows: Section 4.2 formalizes the continuous dose
treatment DTR problem and connects it with observational data; Section 4.3 and
4.4 describes the proposed stochastic spline-involved tree search learning method for
estimating the optimal dosage regime and outlines its implementation; Section 4.5
presents the numeric results from simulation studies; Section 4.6 illustrates the data
application of SSITS using data from the International Warfarin Pharmacogenetics
Consortium. Section 4.7 concludes the study with a discussion.
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4.2 Data and Mathematical Formulation of Dynamic Dosage
Regime
4.2.1 Notation and the Statistical Problem
We assume there are T stages in total. At each stage t ∈ {1, 2, . . . , T}, we denote
the continuous dose value of the drug taken at stage t by Dt ∈ Dt, and the observed
value of Dt is dt. Without loss of generality, we further assume the domain of the
dose assignment Ds = [0, 1], and dt ∈ Dt. Let Xt denote the patient information
accumulated between stage t − 1 and t, and the patient history up to stage t can
be denoted as Xt = (X1,X2, . . . ,Xt). Similarly, the treatment history until stage
t can be denoted as Dt = (D1, . . . , Dt−1). The outcome of interest is denoted by
Y . In practice, the reward outcome we are interested in might be a combination of
some intermediate outcomes, or the outcomes happen after some intermediate stages
may have an impact on the final outcome. Thus, the overall outcomes vector is
(Y1, Y2, . . . , YT ) and the outcome history Yt−1 = (Y1, . . . , Yt−1). We further denote
that the final outcome of interest Y is a function of all intermediate outcomes, i.e., Y =
s(Y1, Y2, . . . , YT ), where s(·) is a pre-specified function (e.g., sum). We assume Y to
be bounded and higher value of Y is more desirable. We define the history prior to the
dose treatment at stage t Dt as Ht. which includes the dose assignments Dt−1 history,
the history happened before stage t, Xt, and the intermediate outcomes. Specifically,
Ht = {(Dt−1,Xt,Yt−1)}ni=1. Therefore, across patient index i, the observed data
consist n i.i.d. trajectories are denoted as {Dt,i,Ht,i, Yt,i}Tt=1. For brevity, we suppress
the subject index i in the following text when no confusion exists.
The goal of our method is to use the observed data to find the optimal dosage
regime that determines, based on a patient’s medical history, what dose he/she should
receive at each stage. We formally define a personalized decision rule sequence
g = (g1, g2, . . . , gT ) as the dynamic dosage regime, where gt, the decision rule of
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stage t, maps the observed history Ht about the patient’s health history to the dose
assignment, i.e.,
Ht 7→ gt(Ht) ∈ Dt, t ∈ {1, 2, . . . , T}
The counterfactual framework of causal inference proposed by Robins (1986) is
followed to identify the optimal dynamic dosage regime from the observed data. The
counterfactual outcome if a patient follows the dynamic treatment regime g is denoted
by Y ∗(g). E(Y ∗(g)) is the expectation with respect to the distribution of patients’
history of the counterfactual outcome if the entire population had followed the given
dosage regime g. The optimal dosage regime gopt should be a sequence of decision
rules that is able to make the entire population benefit from it. Therefore, we formally
define the optimal gopt as a sequence of decision rule that can lead to the optimal
value of E{Y ∗(g)}, such that,
E{Y ∗(gopt)} ≥ E{Y ∗(g)}, ∀g ∈ G, (4.1)
where G is the set of all potential dosage regimes under consideration.
4.2.2 How to Use the Observational Data
In Eqn (4.1), the expectation of counterfactual is utilized to estimate the opti-
mal dosage regime. Considering the limited accessibility of counterfactual outcome,
which often comes from the data of randomized clinical trials, we have to connect the
counterfactual outcome with the data we observe by applying the framework and as-
sumptions of causal inference (Robins , 1986). In particular, the method to estimate
the whole optimal dynamic dosage regime includes backward induction; therefore,
we start formulating this optimization problem from the final stage T in a reverse
sequential order. At the final stage T , let Y ∗(D1, D2, . . . , DT−1, dT ), or Y ∗(dT ) for
brevity, denote the counterfactual outcome if a patient takes dose dT conditional on
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his/her previous medical characteristics. In order to better connect the counterfactual
outcome Y ∗(dT ) with the observed data {DT ,HT , Y }, we make the following causal
inference assumptions:
Assumption 1 Consistency : DT = dT implies Y = Y
∗(dT ). This assumption
ensures the observed outcome is the same as the counterfactual outcome under
the dose actually assigned.
Assumption 2 Exchangeability : Y ∗(dT ) ⊥ DT | HT , ∀ dT ∈ DT , where ⊥
denotes statistical independence. This assumption guarantees that the coun-
terfactual outcome under a certain dose dT is independent of the dose choice,
conditional on the previous history HT .
Assumption 3 Positivity : pi(dT | HT ) ≥ pimin > 0 for all possible HT , where
pi(dT | HT ) = ∂P (DT≤dT |HT )∂dT is the conditional treatment density given history
HT and pimin is a given positive number. It ensures that every patient has some
chance of receiving a certain treatment dT
Under the assumptions above, the expectation of counterfactual outcome Y ∗(dT ) can
be identified from the observed data as
E{Y ∗(dT )} = E{E(Y | DT = dT ,HT )} =
∫
HT
E(Y | DT = dT ,HT = hT ) dP (hT ).
Dose-response function is a natural way to visualize the dose-response relationship
and researching the continuous dose effect (Kennedy et al., 2017; Zhao et al., 2020),
therefore, we denote θT (dT ) = E(Y
∗(dT )), and θT (·) is the dose-response function of
the population we are interested in. To guarantee that the optimal dose is identifiable
within the domain, we have another assumption:
Assumption 4 Concavity : θT (·) is continuous on the closed interval of DT
and differentiable on the open interval of DT ; the second derivative θ′′T (·) exists
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throughout DT and θ′′T (dT ) < 0 ∀ dT ∈ DT . This assumption ensures the existence
of the local maximum of the dose-response function within the domain DT .
Let θT{gT (HT )} denote the dose response of the outcome under regime gT . According
to Eqn (4.1), the optimal regime of the final stage goptT (HT ) satisfies
E[Y ∗{goptT (HT )}] ≥ E[Y ∗{gT (HT )}], ∀ gT ∈ GT .
i.e.
goptT (HT ) = arg max
gT∈GT










At the intermediate stage t ∈ {1, 2, . . . , T − 1}, it is important to compare the
decision rules of a intermediate stage when the decision rules after the current stage
are the same, unless the comparison becomes meaningless. Thus, we compare the
decision rule of the current stage while assuming their future dose assignments have
been optimized. We denote the future optimized counterfactual outcome with all fu-
ture stages dose assignments under the optimal decision rules, when a patient at stage
t receiving treatment dt as {Y ∗(D1, . . . , Dt, goptt+1, . . . , goptT )Dt=dt}, for brevity Y˜ ∗t (dt).
Under similar causal inference assumptions, the expectation of the future opti-
mized counterfactual outcome can be identified through observed data as E(Y˜ ∗t (dt)) =
E{E(POt | Dt = dt,Ht)}, where POt denotes pseudo-outcome of stage t. Specifically,
we define POt recursively using Bellman’s optimality as POt = Eˆ{POt+1 | Dt+1 =
goptt+1(Ht+1),Ht+1} and POT = Y .
Similarly, we can define at any stage θt(dt) = E{Y˜ ∗t (dt)}, where θt(·) is the dose-
response function of the entire population at stage t, and the concavity of θt(·) should
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be assumed throughout the domain of Dt. Thus, the dose-response function at stage
t under a decision rule gt(Ht) is denoted as θt{gt(Ht)}. goptt (Ht) should satisfy
E[Y˜ ∗t {goptt (Ht)}] ≥ E[Y˜ ∗t {gt(Ht)}], ∀ gt ∈ Gt, we have the optimization problem at
the intermediate stage t becoming









4.3 Stochastic Spline-Involved Tree Search for Optimizing
Personalized Multi-stage Dosage Regime
Decision tree is one of the most popular models for interpretable statistical learn-
ing. To estimate a tree-based decision rule, the tree-based reinforcement learning
method (Laber and Zhao, 2015; Tao et al., 2018) can be a natural option. LZ recur-
sively splits the patient feature space by maximizing the purity measure at each split.
Such a top-down, greedy algorithm may end up estimating a local optimal decision
rule when there are strong predictors hidden from imperceptible parent nodes. One
way to alleviate the greediness is lookahead by finding new splits based on optimizing
deeper trees rooted at the current terminal node, rather than just optimizing a single
split (Murthy and Salzberg , 1995; Tao et al., 2018). However, lookahead is still heavily
limited by its local move, since it generates a sequence of trees, each of which is an
extension of the previous tree. It does not resolve the problem of local optimality
while increasing the computational burden substantially (Bertsimas and Dunn, 2017;
Tao et al., 2018).
Constructing an optimal decision tree is known to be NP-complete (Laurent and
Rivest , 1976), here we propose to use stochastic tree search to expand the search scope
and to better balance the exploration and the exploitation. Within each terminal
node, a flexible smooth coefficient model is used to model the dose-response function
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while adjusting for confounders.
4.3.1 Estimating the Dose-response Function
The estimator of the dose-response is vital in assessing the quality of estimated
dosage strategy. To estimate the dose-response function using observational study
data, the key is to adjust for the confounding variables. Rosenbaum (1987) developed
the propensity score method to address the confounding bias for binary treatment
assignment, and other statisticians have proposed generalizations of the propensity
score method to deal with continuous treatment (Imai and Van Dyk , 2004; Hirano
and Imbens , 2005; Flores et al., 2012). In particular, the propensity function (PF)
used a generalized propensity score-based method for causal inference with continuous
treatments (Imai and Van Dyk , 2004).
The propensity function piψ(Dt | Ht) is defined as the conditional density function
of a dose assignment given the observed history at stage t ∈ {1, . . . , T}, where ψ
parameterizes this distribution. We further fit the parametric model of the propensity
function as eψ(· | Ht) = piψ(· | Ht). In addition to the assumptions from Section 2
above, we make another assumption to simplify the representation of PF. We assume
a Uniquely Parameterized Propensity Function. In particular, for every value of Ht ∈
Ht, there exists a unique finite-dimensional parameter φ ∈ Φ, such that eψ(· | Ht)
depends on Ht only through φψ(Ht). In other words, the propensity function e(· |
φψ(Ht)) can be uniquely represented by φ. Therefore, we can rewrite PF as e(· | φ),
where φ = φψ(Ht). This parametrization assumption that uses φ to represent Ht
can decrease the dimension in future calculations when adjusting for confounders, as
φ has typically much lower dimension than Ht. Without loss of generality, we specify
φ as univariate, and rewrite φ as φ. In the case of continuous treatment, we can
assume the treatment Dt ∼ N(βHt, σ2), where ψ = (β, σ2). Finally, φψ(Ht) = βHt
can uniquely represent the propensity function e(· | φψ(Ht)).
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4.3.1.1 Use a smooth coefficient model to estimate the dose-response
function
The dose response can be estimated by matching or subclassifying on the propen-
sity function. However, the method we may use in subclass models may be con-
strained due to the dependency on the parametric assumptions within the subclass
models; therefore, to better understand the dose-response relationship in practice,
we prefer estimating a robust and flexible dose-response function. We further fit the
dose-response model using a smooth coefficient model (SCM), also known as vary-
ing coefficient model (Hastie and Tibshirani , 1993; Zhao et al., 2020). This model
allows the regression coefficients to vary smoothly and systematically in more than
one dimension as a function of the propensity function and the dose assignment Dt.
At the final stage T , according to the uniquely parameterized assumption of the
propensity function, the dose-response function can be re-written as
θT (dT ) = E(Y
∗(d)) = E{E(Y | DT = dT ,HT )} = E{E(Y | DT = dT , φT )}, (4.4)
where φT = φψ(HT ) is the propensity function at the final stage T . We can model
the rightmost part of Eqn 4.4, E(Y | DT = dT , φT ) using a smooth coefficient model,
i.e.,
E(Y | DT = dT , φT ) = f(φT , DT ),
where f(·) is a smooth function of φT and DT . In practice, φT is replaced by φ̂T
from the fitted propensity function. Therefore, we can average over the empirical
distribution of φT to obtain an estimate of the dose-response function using a SCM
of the PF, such as






f̂(φ̂T,i, dT ), (4.5)
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where f̂(·) is the fitted SCM and φ̂T,i is from the fitted propensity function. The
dose-response function can be evaluated in Eqn 4.5 separately, using a pre-specified
grid of dose values within the domain DT .
At any intermediate stage t ∈ {1, 2, . . . , T − 1}, the future optimized Y ∗t (dt)
is not observable and needs to be replaced with the future optimized pseudo out-
come as defined previously. The estimation of θ̂T (dT ) above works for any stage
t ∈ {1, 2, . . . , T − 1} prior to the final stage T . In the implementation, the SCMs
are fitted using the R package “mgcv” (Wood , 2017), and the smooth functions are
represented as a weighted sum of known basis functions, which are penalized cubic
regression splines with the number of knots equal to 5. Cubic spline is utilized as it is
flexible but also smooth enough to capture the curve. According to our preliminary
simulation studies, we varied the number of knots from 5 to 10, and the estimation
of the dose-response function stayed robust.
4.3.2 Simulated Annealing Algorithm for Stochastically Searching the
Optimal Dosage Regime
Simulated annealing is an algorithm inspired by a powerful optimization process
that happens during the cooling of physical systems (Salter and Pearl , 2001; Wang
et al., 2017). The goal of the cooling process is to obtain a solid that has minimal
energy. This intuition can be generalized to other optimization goals; in our case, the
goal is to find an optimal dosage regime that maximizes the expected counterfactual
dose response outcome of the whole population. In practice, the optimal decision
rule of each treatment stage within the dosage regime is estimated backwards in a
reverse sequential order; therefore, in the following derivation, the algorithm works
for any treatment stage t; for convenience, we suppress the stage subscript t when no
confusion exists. Formally, we denote a tree-based continuous dose decision rule as
g. g can be evaluated using a value function F (g), which is intended to be optimized
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to identify the optimal decision rule. The simulated annealing algorithm proceeds by
walking stochastically through the tree space in such a way that a decision rule g that
increases the value of F (g) is always accepted while those that decrease the value can
be accepted with a specific probability. This probability depends on the number of
iterations and other pre-specified hyper parameters. The simulated annealing algo-
rithm may accept a worse solution in order to help the optimization process proceed
and avoid being trapped in a local optimality.
Let T0 be the initial temperature parameter, and let Niter be the total number
of iterations. These two hyper parameters and the formula of temperature change
control the rate of identifying the optimal solution and are critical for obtaining a
robust optimal solution. In particular, if the temperature decreases too quickly, the
algorithm might be trapped within a local optimal point, while the slower temperature
decrease can require excessive computational efforts. In our implementation, we set
T0 = 100. Let m be a specific iteration, m ∈ 1, 2, . . . , Niter, let gm be the tree-based
decision rule at iteration m, and let Tm be the temperature at iteration m. The
following steps are repeated until m reaches Niter:
1. For the current dose decision rule gm, generate a potential decision rule gm′ from
gm according to the generation procedure;
2. Calculate F (gm′);
3. Accept gm+1 = gm′ with probability min{1, exp(F (gm′)−F (gm)
Tm
)}, otherwise gm+1 =
gm;




We further specifically denote the dose decision rule g as (P ,R), where P is the
parameter set that describes a tree topology, and R is the optimal dose assignment
rule for each terminal node of P . At each iteration m, the new solution can be
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generated via two steps: first generate a tree topology Pm , and then identify the
dose assignment ruleRm based on Pm. Thus, gm can be evaluated and the acceptance
can be determined accordingly.
When generating gm′ from the current solution gm, we have to first generate the
tree topology Pm′ from Pm. In particular, a tree topology consists of three elements:
tree arrangement, splitting variables and splitting thresholds. Our algorithm proposes
generating Pm′ from a solution that is neighboring to Pm, rather than generating it
uniformly. To be more specific, the neighboring tree topology we use is generated
by five different proposals, namely, GROW, PRUNE, CHANGE, SWAP and RE-
STRUCTURE (Denison et al., 1998; Chipman et al., 1998; Wu et al., 2007). The
GROW proposal randomly picks one terminal node from the current tree P and splits
it into two new terminal nodes. The PRUNE proposal is the reverse of GROW as
it randomly picks one parent node with two terminal nodes and collapses its termi-
nal nodes and turns the parent node into a terminal node. The CHANGE proposal
randomly picks a non-terminal internal node and resamples the splitting rule. The
SWAP proposal randomly picks a pair of parent-child internal nodes and swaps their
splitting rules. Considering the restricted change these proposals make to the current
Pm, we also propose a more radical change of the tree structure, called RESTRUC-
TURE (Wu et al., 2007). The RESTRUCTURE proposal modifies the structure of
the internal nodes while maintaining the number of terminal nodes and the partition
of the subjects. This radical change helps the proposed decision tree escape from the
local optimality and search more efficiently within the tree topology space. The five
proposals are implemented with pre-specified probabilities.
For a given tree topology P , the next step is to identify the optimal dose assign-
ment rule R. Let b(P) denote the set of all terminal nodes and v ∈ b(P); R denote
the dose assignment rule that assigns specific dose dv to each terminal node v. We
can further define the objective function F (g) as a sum of each subpopulation dose
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response, such as, F (g) =
∑
v∈b(P) θˆv(dv)Pn[I(H ∈ v)], where Pn is the empirical ex-
pectation operator, and θˆv(dv) is the estimated expected counterfactual dose response
if all subjects in terminal node v take dose dv. Since the identification of the optimal
decision rule happens by maximizing the expected counterfactual dose response, as-
signing any random dose dv to each terminal node v is reasonable but not efficient.
In this case, a large proportion of the population does not receive their optimal dose,
and thus the random dose assignment does not maximize our objective in the given
tree topology. Alternatively, in order to maximize F (g), R assigns dose doptv to each






v )Pn[I(H ∈ v)]. (4.6)
Since the concavity of θv(·) ensures the existence of the maximum of the dose-response
function, the treatment assignment of each terminal node v can be uniquely deter-
mined. Thus the optimal tree-based decision rule can be identified from the stochas-
tically generated rule sequence via the simulated annealing algorithm. The details
are summarized as in Algorithm 4 below.
4.4 Implementation of SSITS
The proposed method is implemented by backward induction. At each stage,
the optimal dose decision is determined by stochastically evaluating the expected
counterfactual dose response outcome of the proposed tree-based decision rule. Before
estimating the dose-response function of each stage t, we have to estimate the pseudo
outcome POt first, which is the replacement of Y in the intermediate stage. At the
final stage t = T , POt = Y , and it can be used directly to estimate the dose-response
function, thus to estimate the regime. At any intermediate stage t ∈ {1, 2, . . . , T −1},
the pseudo-outcome POt depends on an estimated dosage regimes where the dose
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assignment of the future stages have been already optimized, as POt = Eˆ{POt+1 |
Dt+1 = g
opt
t+1(Ht+1),Ht+1}. We further assume the dose effect Yt is cumulatively
carried forward to the final outcome Y . To reduce the accumulated bias, we calculate
the pseudo outcome POt by using Yt, the actual observed intermediate outcome at
stage t plus the difference of the expected optimal dose-response pseudo outcome and
the expected pseudo outcome of actual observed of the stages after t; that is
POt = Y +
T∑
j=t+1
{E(POj | Hj, Dj = goptj (Hj))− E(POj | Hj, Dj = dj)},
where POT = Y and POt is calculated by using off-shelf machine-learning method
“eXtreme Gradient Boosting” (Chen and Guestrin, 2016). Note here, the interme-
diate outcomes Yt might be different measures of patient’s disease status, such as
toxicity or efficacy, because of the different priority of assigning a dose during the
progression of disease. Therefore, before aggregating various intermediate outcomes
from different stages, the scale should be standardized by clinician’s suggestion. The
implementation of Stochastic Spline-Involve Tree Search for estimating the optimal
dosage regime with T treatment stage is outlined in Algorithm 4. Note here, Niter is
the pre-specified total number of simulated annealing iterations. In practice, to yield
a more robust estimated dosage regime, the Niter iterations can be repeated in mul-
tiple chains using different initial P1. To further promote randomness, in each chain
we start from a random tree sampled from tree-generating process pi(P). Details on
how to generate the initial tree topology can be found in the Appendix.
4.5 Simulation Studies
We conduct a number of simulation studies to assess the performance of SSITS.
To facilitate the comparison with existing methods, we conduct simulation scenarios,
and estimate the optimal dosage regime using methods proposed by CZK (Chen et al.,
83
Algorithm 4 Stochastic Tree Search for the optimal dosing in T -stage decision rules
Result: ĝopt = ĝopt1 , . . . , ĝ
opt
T
Set t = T , POT = Y .
while t ≥ 1 do
Set m = 1
Initialize P1 ∼ pi(P) for stage t
while m ≤ Niter do
1. Propose Pm′ from Pm;
2. Estimate the dose-response functions θ̂t,v(dv) using POt for v ∈ b(Pm′) ;




v )Pn[I(Ht ∈ v)]);








m = m+ 1.
end while
Estimate the optimal decision rule using ĝoptt = arg maxgi:i∈{1,2,...,m} F (gi)
t = t− 1
Set POt = Y +
∑T
j=t+1{E(POj | Hj, Dj = goptj (Hj))− E(POj | Hj, Dj = dj)},
end while
84
2016) and LZ (Laber and Zhao, 2015). CZK is derived from outcome weighted learn-
ing (Zhao et al., 2012) using non-linear kernels. It uses a non-convex loss function
for the dose assignment optimization and solves the optimization problem by using
the difference of convex functions. To accommodate the observational data, we use
support vector regression, as presented by Chen et al. (2016), to estimate the condi-
tional density of having one certain dose treatment. LZ is a tree-based reinforcement
learning method that uses CART to estimate the optimal dosage regime. The purity
measure of LZ is calculated by the kernel estimation using a plug-in bandwidth. The
comparison with CZK and LZ is implemented using R packages “kernlab” (Karat-
zoglou et al., 2004), “SVMW ” (Chen et al., 2016), “gbm” (Ridgeway and Ridgeway ,
2004) and “np” (Hayfield and Racine, 2008). A variety of single- and two-stage sce-
narios are considered. For each scenario, we apply each method on a training set with
a sample size N=300 or 500, and evaluate the estimated regimes on a separate test
set with a sample size N=1000.
4.5.1 Single-Stage Scenarios
We consider single-stage scenarios with a continuous dose and generate baseline
covariates X1, · · · , Xk according to uniform(0, 1). k is the number of baseline vari-
ables. In practice, when the tailoring variables are known by investigators, k can
be small. When the tailoring variables are not fully understood, k will be relatively
large. The dose assignment D1 is set within the range of D1 = [0, 1], generated from
Beta(α, 1−α) with α = 1/{1+exp(0.3X1 +0.2X2 +0.1X3)}, which makes D1 depend
on the observed covariates.
To study the impact of underlying model specification on the performance of
SSITS, two forms of the underlying optimal dosage regimes gopt1 (H1) are considered,
one a tree-type dosage regime (Scenario 1, 2, 3), the other a non-tree-type regime
(Scenario 4, 5, 6 and 7). The underlying tree-type is consistent with the dose as-
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signment model when using the proposed stochastic tree search algorithm, while the
models with underlying non-tree-type are “mis-specified.” The detailed specification
of gopt1 (H1) can be found in Table 4.1
These various non-tree-type scenarios can evaluate the robustness of SSITS against
model mis-specification. In particular, the setting of Scenario 5 is inspired by Chen
et al. (2016); the relationship between observed covariates and the optimal dose is
non-linear and far away from a tree-type regime.
Our continuous outcome Y1 has the form of Y1 = m(D1) + βH1 + 1, where
βH1 = a
∑k
i=1 Xi + b and 1 is an independent standard normal variate that follows
N(0, 1); m(d1) = 1.1× F24,6.75[0.8− (gopt1 − d1)], and Fp,q(d1) is a unimodal function
within the domain to ensure the existence of the maximum dose effect. Specifically,
Fp,q(d1) = (d1)
p−1
1 (1 − d1)q−1Γ(p + q)/{Γ(p)Γ(q)} is the probability density function
of Beta(p, q).
In the data generation process, when the underlying true optimal dose is already
known, we use the training dataset to estimate the optimal regimes and predict the
optimal dose in the testing dataset. We use | dopt− d̂opt | and Ê(Y ∗(ĝopt)) to evaluate
the performance of the methods, where dopt is the known true optimal dose under the
pre-specified underlying optimal regime gopt, and d̂opt is the estimated optimal dose
calculated from the estimated optimal dosage regime ĝopt. | dopt − d̂opt | shows the
average of how close the estimated optimal dose is to the true optimal dose; smaller is
better. Ê(Y ∗(ĝopt)) is the expectation of the estimated mean counterfactual outcome,
which indicates how much the whole population would benefit from the estimated
optimal dose regimes if all subjects were to receive the estimated optimal dose. Since
the results of Ê(Y ∗(ĝopt)) and | dopt − d̂opt | are not normally distributed Sun (2019);
Tao et al. (2018), we present the results of medians with the interquartile range from
25th quartile to 75th quartile.



























































































































































































































































































































































































































































































































































































































































narios described above. In particular, we set k = 5 to mimic the scenarios where
the tailoring variables are clear to clinicians. Thus, a=1.41 and b=0.46. When the
underlying dosage regime is correctly specified, i.e., tree-type, SSITS has consistently
superior performance than LZ and CZK in all settings. Specifically, when sample
size N=500, SSITS correctly assigns most of the patients into their optimal dose, as
| dopt − d̂opt | is close to 0 in Scenario 1, 2, and 3, respectively. The medians of the
estimated mean counterfactual outcome of these three scenarios are also close to the
pre-specified true value 10. When the sample size decreases to N=300, the perfor-
mance gets worse but still outperforms LZ and CZK. The compromised performance of
CZK is to be expected, as this method makes better use of the information of patients
whose observed dose is close to the predicted optimal dose. In other words, if received
dose is not close to the optimal dose for most subjects in the observed data, which
is common in an observational study and is also the case in our simulation setting,
CZK’s performance is substantially undermined. In addition, the worse performance
of LZ might be due to its fragility with severe model misspecification. LZ requires a
correct specification of the conditional density of the model of treatment assignment,
and also a correct specification of an outcome regression model. Mis-specification of
these models may result in estimating a sub-optimal dosage regime.
When the underlying dosage regimes are mis-specified (Scenario 4, 5, 6, and 7),
the performance of SSITS is undermined, but is still better compared to other existing
methods. Furthermore, In scenario 5, 6 and 7 when SSITS largely outperform LZ and
CZK in E{Y ∗(ĝopt)}, the values in | dopt − d̂opt | are close to their counterparts. The
difference of performance is because SSITS identifies the optimal dosage regime by
maximizing the expected counterfactual outcome. In other words, instead of directly
identifying the optimal dose for each individual, SSITS tries to find the optimal regime
that can result in a higher expected counterfactual outcome for the whole population,
which makes a large part of the population benefit from the estimated optimal dosage
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regime.
We further set k = 20, thus a=0.71 and b=-3.07, to mimic a situation when the
tailoring variables that interact with the dose assignment are not clear to clinicians.
In this setting, we intend to see how the noise interference may affect the performance
of our proposed method. The results are summarized in Table 4.3. The comparison
with existing methods shows similar trends as in Table 4.2. SSITS clearly outperforms
the existing methods in most cases, especially in the cases with tree-type underly-
ing dosage regimes. However, SSITS is more sensitive to the increase of covariates
dimension, compared to the existing methods. In particular, CZK performs competi-
tively in Scenario 5 when N=300, which is a complex non-tree-type underlying dosage
regime where the pre-specified optimal dose of each patient cannot be classified to
limited categories. The simulation studies from Chen et al. (2016) also demonstrated
its capability of dealing with some non-linear dosage regime cases, especially with
a small sample size. Our findings here are consistent with their results. The com-
promised performance of SSITS may derive from the lower convergence rate of the
non-parametric method we used in the dose-response model. This is an issue that we
plan on investigating more in the future.
4.5.2 Two-Stage Scenarios
In the setting of dynamic dosage regimes where the treatment decisions are made
at multiple stages, SSITS can be utilized sequentially. Specifically, to apply in a two-
stage scenario, suppose the outcome of interest is the sum of intermediate outcomes
at each stage, i.e., Y = Y1 + Y2. d
Like the single stage scenarios, we also consider the underlying true optimal
dosage regime as tree-type or non-tree-type. The data are generated by extending
the parameter specifications of the single-stage scenarios (Scenario 1 and 4 from the
single-stage scenarios). To help make decisions in the second stage, we generate two
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Table 4.2: Simulation results for single-stage scenarios that use 5 baseline covariates
(100 replications, N=300 or 500). 7 scenarios belong to two types of pre-
specified underlying dosage regime: tree-type dosage regime (I) and non-
tree-type dosage regime(II). E{Y ∗(ĝopt)} = 10
Scenario Method N=300 N=500
E{Y ∗(ĝopt)} | dopt − d̂opt | E{Y ∗(ĝopt)} | dopt − d̂opt |
I
1
LZ 5.86(5.65, 6.34) 0.12(0.10, 0.13) 6.10(5.90, 6.53) 0.11(0.09, 0.11)
CZK 6.44(6.28, 6.62) 0.14(0.13, 0.15) 6.61(6.47, 6.72) 0.13(0.12, 0.13)
SSITS 9.70(9.56, 9.92) 0.02(0.01, 0.03) 9.83(9.65, 9.92) 0.01(0.01, 0.02)
2
LZ 6.32(6.04, 6.65) 0.13(0.11, 0.14) 6.63(6.40, 7.20) 0.11(0.09, 0.12)
CZK 6.34(6.18, 6.46) 0.14(0.13, 0.14) 6.48(6.36, 6.56) 0.13(0.12, 0.13)
SSITS 8.11(7.56, 8.52) 0.10(0.07, 0.12) 9.10(8.37, 9.36) 0.05(0.03, 0.09)
3
LZ 6.13(5.78, 6.55) 0.12(0.11, 0.14) 6.64(6.35, 6.96) 0.10(0.09, 0.11)
CZK 6.56(6.44, 6.66) 0.12(0.12, 0.13) 6.64(6.52, 6.76) 0.12(0.11, 0.12)
SSITS 7.97(7.25, 8.53) 0.08(0.06, 0.11) 9.54(9.41, 9.68) 0.02(0.01, 0.03)
II
4
LZ 5.64(5.46, 5.85) 0.14(0.13, 0.16) 5.77(5.62, 6.01) 0.13(0.12, 0.14)
CZK 6.55(6.40, 6.65) 0.13(0.12, 0.14) 6.63(6.50, 6.77) 0.13(0.12, 0.13)
SSITS 9.20(9.06, 9.28) 0.05(0.04, 0.06) 9.23(9.12, 9.31) 0.05(0.04, 0.05)
5
LZ 6.46(6.18, 6.79) 0.13(0.11, 0.14) 7.11(6.87, 7.32) 0.10(0.09, 0.11)
CZK 7.13(6.88, 7.31) 0.10(0.09, 0.11) 7.26(7.11, 7.37) 0.09(0.08, 0.09)
SSITS 7.22(6.74, 7.61) 0.10(0.08, 0.13) 7.55(7.33, 7.82) 0.09(0.08, 0.10)
6
LZ 6.03(5.69, 6.40) 0.17(0.14, 0.18) 6.42(6.17, 6.77) 0.14(0.13, 0.15)
CZK 6.55(6.41, 6.72) 0.12(0.11, 0.13) 6.71(6.59, 6.84) 0.12(0.11, 0.12)
SSITS 7.24(6.82, 7.62) 0.13(0.11, 0.16) 8.63(8.46, 8.80) 0.08(0.07, 0.08)
7
LZ 6.44(6.07, 6.74) 0.16(0.14, 0.18) 6.90(6.58, 7.12) 0.14(0.13, 0.15)
CZK 6.39(6.26, 6.51) 0.13(0.13, 0.14) 6.55(6.36, 6.67) 0.12(0.12, 0.13)
SSITS 7.34(6.98, 7.84) 0.13(0.12, 0.17) 7.64(7.13, 8.15) 0.12(0.10, 0.15)
a. | dopt − d̂opt | shows the median and its interquartile range of the difference between the true
optimal dose and the estimated optimal dose.
b. Ê{Y ∗(ĝopt)} shows the median and the interquartile range of the estimated mean counterfactual
outcome obtained using the true outcome model and the estimated optimal dynamic dosage
regime.
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Table 4.3: Simulation results for single-stage scenarios that use 20 baseline covariates
(100 replications, N=300 or 500). 7 scenarios belong to two types of pre-
specified underlying dosage regime: tree-type dosage regime (I) and non-
tree-type dosage regime(II). E{Y ∗(ĝopt)} = 10
Scenario Method N=300 N=500
E{Y ∗(ĝopt)} | dopt − d̂opt | E{Y ∗(ĝopt)} | dopt − d̂opt |
I
1
LZ 5.69(5.50, 6.08) 0.13(0.12, 0.15) 5.96(5.76, 6.45) 0.11(0.10, 0.12)
CZK 5.89(5.77, 6.01) 0.18(0.17, 0.19) 6.05(5.92, 6.16) 0.16(0.16, 0.17)
SSITS 9.66(9.56, 9.76) 0.02(0.02, 0.03) 9.70(9.65, 9.76) 0.02(0.02, 0.02)
2
LZ 6.16(5.85, 6.43) 0.14(0.12, 0.16) 6.53(6.20, 6.78) 0.11(0.10, 0.13)
CZK 5.83(5.76, 5.94) 0.17(0.16, 0.18) 5.97(5.87, 6.06) 0.16(0.15, 0.17)
SSITS 7.39(6.94, 8.04) 0.13(0.11, 0.16) 8.28(7.86, 8.79) 0.09(0.06, 0.12)
3
LZ 6.17(5.84, 6.51) 0.13(0.11, 0.15) 6.65(6.25, 6.99) 0.10(0.09, 0.11)
CZK 6.00(5.76, 6.15) 0.16(0.15, 0.18) 6.16(6.05, 6.29) 0.14(0.14, 0.15)
SSITS 7.73(6.88, 8.15) 0.09(0.07, 0.13) 9.17(8.46, 9.40) 0.04(0.03, 0.06)
II
4
LZ 5.47(5.34, 5.71) 0.15(0.14, 0.16) 5.70(5.56, 5.91) 0.14(0.13, 0.15)
CZK 6.02(5.85, 6.11) 0.17(0.16, 0.18) 6.19(6.04, 6.31) 0.15(0.14, 0.16)
SSITS 9.07(8.84, 9.26) 0.05(0.05, 0.07) 9.17(8.95, 9.28) 0.05(0.04, 0.06)
5
LZ 6.36(6.04, 6.57) 0.14(0.12, 0.16) 6.95(6.72, 7.19) 0.10(0.09, 0.12)
CZK 6.32(6.15, 6.45) 0.14(0.13, 0.15) 6.63(6.48, 6.77) 0.12(0.11, 0.12)
SSITS 6.02(5.57, 6.58) 0.18(0.14, 0.22) 6.86(6.41, 7.16) 0.11(0.10, 0.14)
6
LZ 5.94(5.63, 6.27) 0.17(0.16, 0.19) 6.21(5.94, 6.49) 0.15(0.14, 0.17)
CZK 5.97(5.85, 6.07) 0.16(0.15, 0.17) 6.19(6.06, 6.31) 0.14(0.14, 0.15)
SSITS 6.67(6.17, 7.37) 0.16(0.12, 0.19) 7.84(7.54, 8.60) 0.10(0.08, 0.11)
7
LZ 6.17(5.80, 6.53) 0.18(0.16, 0.20) 6.66(6.31, 6.87) 0.15(0.14, 0.17)
CZK 5.92(5.78, 6.03) 0.17(0.16, 0.18) 6.12(6.01, 6.20) 0.15(0.15, 0.16)
SSITS 6.53(6.13, 7.02) 0.20(0.15, 0.23) 6.78(6.31, 7.21) 0.18(0.15, 0.21)
a. | dopt − d̂opt | shows the median and its interquartile range of the difference between the true
optimal dose and the estimated optimal dose.
b. Ê(Y ∗(ĝopt)) shows the median and the interquartile range of the expected mean counterfactual
outcome obtained using the true outcome model and the estimated optimal dynamic dosage
regime.
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time-varying biomarkers X4 and X5, simulated independently from Uniform(0, 1),
in addition to three baseline covariates X1, X2, X3. For the first stage, we gener-
ate D1 from Beta(α, 1 − α) with α = 1/{1 + exp(0.3X1 + 0.2X2 + 0.1X3)}. The
continuous outcome of the first stage Y1 has the form of Y1 = m1(D1) + βH1 + 1,
where βH1 = 0.5X1 + 0.3X2 + 0.7X3 and m1(d1) = 1.1 × F24,24(0.5 − (dopt1 − d1));
and dopt1 is the optimal dose under the optimal dosage regime g
opt
1 . We assume
the independent standard normal variate 1 ∼ N(0, 1). Specifically, the under-
lying optimal dosage regime of stage 1 for the tree-type dosage regime is speci-
fied as gopt1 (H1) = 0.8I(X1 > 0.7) + 0.2I(X1 ≤ 0.7)I(X2 ≤ 0.5) + 0.5I(X1 ≤
0.7)I(X2 > 0.5).The optimal dosage regime for the non tree-type is specified as
gopt1 (H1) = 0.8I(X1 +X2 > 1.2) + 0.2I(X1 +X2 ≤ 1.2)I(X2 ≤ 0.5) + 0.5I(X1 +X2 ≤
1.2)I(X2 > 0.5). At the second stage, the treatment assignment D2 is also generated
from Beta(α, 1− α) with α = 1/{1 + exp(0.3X5 + 0.2X5 + 0.1X3)}. The continuous
outcome Y2 = m2(D2)+βH2+2, where βH2 = 0.3X1+0.2X2+0.5X3+0.6X4+0.2X5
and m2(d2) = 1.1×F24,24(0.5− (dopt2 − d2)). Again, we assume 2 ∼ N(0, 1). The un-
derlying optimal dosage regime of stage 2 for the tree-type dosage regime is specified
as gopt2 (H2) = 0.8I(Y1 > 4) + 0.2I(Y1 ≤ 4)I(X4 ≤ 0.5) + 0.5I(Y1 ≤ 4)I(X4 > 0.5).The
optimal dosage regime for the non tree-type is specified as gopt2 (H2) = 0.8I(Y1 +X5 >
4.2) + 0.2I(Y1 +X5 ≤ 4.2)I(X2 ≤ 0.5) + 0.5I(Y1 +X5 ≤ 1.2)I(X2 > 0.5).
Results for different sample sizes and underlying optimal dosage regimes are shown
in Table 4.4. Given a tree-type underlying dynamic dosage regime with a sample size
N=300, the median of the estimated mean counterfactual outcome of two stages of
SSITS is 18.21, which is fairly close to the optimal value of 20. The median of
the estimated mean counterfactual outcome is 8.45 for stage 1 and 9.94 for stage 2.
The better performance of the second stage is as expected, because we adapt the
backward induction to start the estimation from the final stage. In contrast, CZK
only has 11.24 in the median of the estimated mean counterfactual outcome, and LZ
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is 10.54. A similar superiority of SSITS is also found under non-tree-type underlying
dynamic dosage regimes and a larger sample size N=500. Moreover, when the sample
size increases, the performance of all methods is better. Specifically, the convergence
rate of the dose-response function using non-parametric models is much slower than
that of the parametric case; therefore, the relatively compromised performance with
a smaller sample size is also to be expected. Moreover, when the underlying true
dynamic dosage regime is misspecified, i.e., under the non-tree-type scenario, the
performance of SSITS is still reasonably satisfactory, with Ê(Y ∗(ĝopt)) = 17.28 when
N = 300 and with Ê(Y ∗(ĝopt)) = 17.33 when N = 500. It shows that SSITS is robust
against mis-specification of the underlying true model.
4.6 Real Data Application: Estimating an Optimal Warfarin
Dosage Regime
We illustrate the application of SSITS by an analysis of the data from The In-
ternational Warfarin Pharmacogenetics Consortium (2009) (IWPC). Warfarin is a
commonly used anticoagulant medicine worldwide, and appropriate Warfarin dosing
is critical in clinical practice. In particular, overdosing patients poses a high risk of
bleeding, while underdosing undermines Warfarin’s treatment effect against throm-
bosis.
Identifying the optimal dose for Warfarin is still an open problem in the clinical
community (Kimmel et al., 2013; Fredrikson et al., 2014). To predict the optimal
Warfarin dose, IWPC proposed three linear regression models, which are modeled by
clinical data, pharmacogenetics-clinical data, and fixed single-dose data, respectively.
Such linear regression models are valid when most of the patients from the training
dataset receive the optimal dose. However, later studies (Holbrook et al., 2005) have






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































subgroups, e.g., elderly patients.
Therefore, to improve the accuracy of existing dosage algorithms and give clini-
cians more insights into treating patients with heterogeneous characteristics, an indi-
vidualized dosage strategy becomes an ideal solution. In the following analysis, we use
SSITS to estimate the optimal Warfarin dose, and provide an interpretable optimal
dosage regime. According to the previous dose prediction linear regression models, the
pharmacogenetics-clinical model had better performance for predicting the optimal
dose, compared with the two other models. Therefore, we included both pharmaco-
genetics and clinical variables into the analysis, such as age, gender, height, weight,
CYP2C9 genotype, VKOOC1 genotype and the medication status of Cytochrome
P450 enzyme and Amiodarone. Following Wallace et al. (2018); Chen et al. (2016),
after excluding patients with missing values, there remained a total of 1498 patients
with a weekly Warfarin dose ranging from 4.5 mg to 315 mg. In clinical practice, INR
(the international normalized ratio), an index that measures the rapidity of blood
clotting, is used to evaluate the treatment effect of Warfarin. For patients treated
by Warfarin, the target INR is 2-3 and INR=2.5 is the ideal outcome. Thus, we
converted the observed INR into a reward outcome as 2 −√| 2.5− INR | for each
patient; larger values were preferable.
We set hyper-parameters of SSITS based on potential clinical needs. In particular,
we set the minimum node size=150. This is a setting where clinicians expect to see
more tailoring variables in a complex tree-based dosage regime, since the number of
patients in the terminal nodes is small.
The estimated dosage regime is shown in Figure 4.1. If a patient is an African
American, it suggests a lower dose of 17.5 mg Warfarin per week. For the patients
who are from other races and are older than 57, they should take 28 mg per week
is recommended if they do not have VKOOC1 AG mutation; otherwise they are rec-
ommended to take 17.5 mg per week. For the patients who are from other races and
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Figure 4.1: The estimated optimal Warfarin dosage regime estimated by SSITS using
observational data from International Warfarin Pharmacogenetics Con-
sortium.
younger than 60, the ones with VKOOC1 AA mutation, it is recommended to take
42.5 mg per week while the remaining patients should take 37.5 mg. These dose sug-
gestions derived from the estimated dosage regime have consistent trends with what
has been reported in the literature (The International Warfarin Pharmacogenetics
Consortium , 2009; Holbrook et al., 2005). In conclusion, SSITS is able to reveal
some potential tailoring biomarkers that an optimal dose should be based on, and
also shows its capability in estimating an individualized interpretable optimal dosage
regime.
4.7 Discussion
Considering the limitations of current methods when estimating the optimal dy-
namic dosage regime, we developed the SSITS method to estimate the personal-
ized optimal dosage regime. SSITS, which combines a robust non-parametric dose-
response function with an efficient simulated annealing stochastic search method, has
shown its consistently superior performance over existing methods in our comprehen-
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sive simulation studies. In particular, even though the underlying optimal dosage
regime of SSITS is not tree-type decision rule, SSITS still shows satisfactory perfor-
mance when the underlying true optimal dosage regimes are mis-specified. In addition
to the robustness, the easy-to-implement SSITS is able to provide interpretable de-
cision rules. These make it particularly useful for clinicians to understand and apply
the estimated regime with confidence. For a newly presenting patient, clinicians do
not need to do extra complicated calculation and they are able to determine a rec-
ommended dose assignment right away.
According to the simulated annealing algorithm, the outcome of the iteration
only depends on the outcome of the previous iteration, but the transition probabili-
ties change with the number of iteration; therefore, the simulated annealing algorithm
creates a time-inhomogeneous Markov chain. Under certain conditions, the discrete-
time discrete-state Markov chain created by simulated annealing has been shown to
converge to a stationary distribution of the optimal solution (Lundy , 1985; Lundy and
Mees , 1986; Granville et al., 1994). In practice, the convergence to global optimal re-
quires excessive computational resource while the satisfactory empirical performance
is straightforward to be obtained. One future research direction lies in further improv-
ing the computational efficiency of simulated annealing algorithm by incorporating
methods from other discrete-space search approaches (Osman, 1995). Moreover, when
increasing the number of covariates, the number of candidate decision trees have to
be visited increases inevitably. Therefore, improving the algorithmic efficiency is also
critical when applying this method in more complex dataset.
In addition, overfitting can be a problem in the procedure of estimation, since it
is non-trivial to make inference for the estimated optimal tree-based decision rule. To
overcome this issue, we may further incorporate the variance of dose response or other
measure of uncertainty into the objective function F (·). That way, the tree with a
high value in the objective function might be penalized for considerable uncertainty,
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and thus the tree with the second or third highest value might be selected as the
optimal one due to a more stable dose response.
Another possible direction is to extend our proposed method to other types of out-
comes, such as binary outcomes, or time-to-event outcomes, as these outcomes are
very common in clinical practice of oncology. How to balance the potentially com-
peting or composite outcomes to determine the optimal dosage regime is also of great
research interest. In clinical practice, clinicians may be interested in determining the
optimal dosage regime according to multiple competing outcomes, such as overall sur-
vival, incidence of local progression, patient preference and quality of life. In order to
balance these contradictory objectives, some statistical methods have been developed
for multi-objective optimization, but none is able to estimate the optimal dosage on a
continuum within the framework of dynamic treatment regime. One potential future
direction is to further incorporate these multiple objective optimization functions and
combine different objectives from different treatment stages, to estimate a practical
and also viable optimal DTR.
98
CHAPTER V
Summary and Future Research Directions
In this dissertation, we have developed new statistical learning methods to evaluate
dynamic treatment regimes, including estimating the test-and-treat decision rules
using a new step-adjusted tree-based reinforcement learning method, and developing
methods to estimate a robust and interpretable DTR with continuous dosage options.
The SAT-Learning method outlined in the second chapter is an important addi-
tion to the current DTR research on multi-stage and multi-treatment decision mak-
ing. It provides health-care recommendations for testing and treating patients over
time. We estimated the test-and-treat strategy by evaluating each test step and every
treatment step embedded within each test step over multiple treatment stages. This
step-adjusted DTR framework may have a greater impact with the rise of awareness
of test screening when more screening data is available and more timely decisions
regarding test-and-treat scheduling have to be made (White et al., 2017; Robertson
and Ladabaum, 2019).
In Chapter III and Chapter IV we studied two methods evaluating the dynamic
treatment regimes with continuous treatment dosages. Assigning continuous doses
over time is particularly important in treating patients with chronic diseases. By com-
bining the DTR framework with the optimal individual dosing strategy, our methods
SSITS and KIDD-Learning provide effective tools for physicians to offer more per-
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sonalized doses over time. The stochastic tree search applied in SSITS allows the
consideration of a richer number of candidate decision rules with an acceptable com-
putational effort. In addition, the non-parametric method we used also relaxes the
assumptions about the model of outcome and the structure of the candidate decision
rule, and guarantees the flexibility of our methods.
We used the top-down tree-based reinforcement learning method to split the de-
cision rule to compromise between exploration and exploitation in Chapter II and
Chapter III; this method is improved in Chapter IV by stochastically walking within
a broader space of decision trees. However, the number of decision rules will in-
evitably increase with the increasing number of tailoring variables, and the computa-
tional time will increase accordingly. One future research direction lies in improving
the computational efficiency by incorporating other methods (Cohen et al., 2003; Qin
et al., 2017) when applying our methods in more complex scenarios. Another research
direction lies in further developing a variable selection method to screen potential tai-
loring variables for estimating the optimal DTR using observational datasets when
high-dimension covariates exist (Wallace et al., 2019; Zhu et al., 2015).
Other extensions can also be considered to avoid the overfitting in the process
of evaluating optimal DTR. Currently, the decision rule with the highest expected
counterfactual outcome is chosen as the optimal rule. We might consider incorpo-
rating the uncertainty of this expected counterfactual outcome by penalizing some
decision rules if they have high uncertainty, such as large variance. In this way, a
decision rule with second or third highest expected counterfactual outcome might be
acceptable due to the more stable performance. This can be extremely useful when
the candidate treatment is on a continuous scale.
Another direction is to explore how to effectively balance the potentially contra-
dictory outcomes and then to determine the optimal DTR. In clinical practice, the
multiple competing outcomes may include incidence of local progression, patient pref-
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erence, quality of life and cost burden (Butler et al., 2017). In order to balance these
contradictory objectives according to clinical needs, some statistical methods have
been developed, but none has been generalized the framework of dynamic treatment
regimes (Lizotte and Laber , 2016; Laber et al., 2014). Incorporating these multiple
objective optimization functions and aggregating different objectives from different
treatment stages would be of great research interest in the future to estimate an





Stopping Rules for Chapter II
Algorithm 5 Stopping Rules
if the node size is less than 2n0 then
the node will not be split
end if
if all possible splits of a node result in a child node with size smaller than n0 then
the node will not be split
end if
if the current tree depth reaches the user-specified maximum depth then
the node will not be split
end if
Calculate the best split by
ω̂opt = argmax
ω
[Psj(Ω, ω) : min{nPnI(Hsj ∈ ω), nPnI(Hsj ∈ ωc)} ≥ n0] .
if the maximum purity improvement Psj(Ω, ω̂opt)− Psj(Ω) < λ then
the node will not be split
else




Simulation Data Generating Process for Chapter
II
Three covariates, X1 to X3, generated as baseline covariates follow N(0, 1). Two
correlated covariates, X4 and X5, are generated as time-varying biomarkers which are
measured just before the decision time of the test step within each stage. (X4, X5)
′ ∼





. After the test step of each stage,
the covariates X12 and X22 mimic the test results that contribute to the treatment
decision nested within each test decision with other covariates. Typically, the test
results, such as biopsy results, are of great importance to the treatment decision
making. X12 and X22 follow the distribution of N(0, 1). To make the rates of taking
the curative treatment equal to 5%, 15%, 20% and 25% in both stages, we also modify
the parameters in the data generating models. More details of parameter setting are
as follows:
Data Generation for Stage 1 The test decision variables, i.e., D11 and D21 are
set to be the values of {0, 1} at the first step of each stage. For stage 1 step 1, we
generate D11 from a Bernoulli(pi11,1) distribution with pi11,1 = exp(0.2X3 + X4 −




4 + (0.5X3 + 4)
2 × I[gopt11 (H11) = D11] − 3|X1|I(D11 = 1) + 11 with optimal
regimes as
gopt11 (H11) = I(X1 > 0.3)I(X4 ≤ 1.3)
and 11 ∼ N(0, 1).
For patients who have been assigned the test, i.e., D11 = 1, we further generate




exp(0.5X12 −X2 − 3.3)/(1 + exp(0.5X12 −X2 − 3.3)) for rate=5%
exp(0.5X12 −X2 − 2.3)/(1 + exp(0.5X12 −X2 − 2.3)) for rate=15%
exp(0.5X12 −X2 − 1.8)/(1 + exp(0.5X12 −X2 − 1.8)) fort rate=20%
exp(0.5X12 −X2 − 1.5)/(1 + exp(0.5X12 −X2 − 1.5)) for rate=25%





12 (H12) = 1) − 1] + I(D12 = 1)(X212 + 4) + 12 with 12 ∼ N(0, 1).
The tree-type optimal regime at step 2 is specified as
gopt12 (H12) = I(X4 > 0.5)I(X12 ≤ 0.3)
Data Generation for Stage 2: In stage 2, we generate the test decision D21 ∼
Bernoulli (pi21,1) with pi21,1 = exp(−0.7 + 0.1X2 +X5)/(1 + exp(−0.7 + 0.1X2 +X5)).




2 + (8−X5)I[gopt21 (H21) =
D21]− I(D21 = 1) + 4.5I(D21 = 1)[I(gopt21 (H21) = 1)−1] + 21 with 21 ∼ N(0, 1). The
optimal regime is specified as
gopt21 (H21) = I(X2 < 0.8)I(X5 > 0.1)
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Among the patients who have had the test in the first step of stage 2, i.e., D21 = 1
we generate their treatment assignment D22 for the second step of the second stage.




exp(0.5X22 −X2 − 3.3)/(1 + exp(0.5X22 −X2 − 3.3)) for rate=5%
exp(0.5X22 −X2 − 2.3)/(1 + exp(0.5X22 −X2 − 2.3)) for rate=15%
exp(0.5X22 −X2 − 1.8)/(1 + exp(0.5X22 −X2 − 1.8)) for rate=20%
exp(0.5X22 −X2 − 1.5)/(1 + exp(0.5X22 −X2 − 1.5)) for rate=25%
The reward of stage 2 step 2 is generated as Y22 = 3I[D22 = g
opt
22 (H22)](2X22−X5)2 +
Y21/3 + (2X4 + X1) + 22 and 22 ∼ N(0, 1). The optimal treatment for stage 2 is
specified as
gopt21 (H21) = I(X22 < 0.3)I(X5 > 0.5)
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APPENDIX C
Data Preprocessing for Active Surveillance Data
for Chapter II
For the prostate cancer data the exclusion criteria were the following: patients who
did not have any PSA observations in the first 4 years were excluded and patients
who were not followed after year 4 are excluded. For the remaining patients if they
did not have a biopsy, the most recent PSA value that was used in the analysis was
the last PSA within the time window between year 0 and year 2 for stage 1 and the
last PSA value between year 2 and year 4 for stage 2. For patients who had a biopsy
test, the most recent PSA for that test is the PSA value right before the date of
biopsy. If a patient had more than one biopsy within a stage, we used the last biopsy
result.
To assess the sensitivity of the estimated DTR tree in Figure 2.2 to modifications
of the reward, we included an additional discounting factor for the reward of patients
who had an especially high risk of future metastatic prostate cancer. Specifically,
when a patient had his Gleason score ≥ 7 (4+3) during the first four years after
diagnosis, his reward is reduced by a factor of 95%. The new estimated trees were
very similar to the estimated optimal DTR shown in Figure 2.2, the only differences
being small changes is the splitting thresholds at each node.
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APPENDIX D
Generation Process of the Initial Tree P1 for
Chapter IV
In a given iteration m, we assume Pm is sampled from pi(P). We further specify
the tree topology model pi(P) using a stochastic tree-growing process, which can be
decomposed as
pi(P) = pi(T )pi(ρ | T )pi(η | ρ, T ),
where T is the tree topology, which includes the number of terminal nodes and how
they are arranged; ρ denotes the splitting variables; η is the splitting thresholds.
A critical component of the specification of pi(P) is the specification of pi(T ),
which controls the number of terminal nodes and the skewness of the tree structure.
A simple and intuitive way of growing a tree skeleton includes two steps: (1) sample
the tree size, i.e., number of terminal nodes from a distribution; (2) cascade down
these terminal nodes from the root like pouring pin balls. We draw the tree size k(T )
from a Poisson distribution k(T ) ∼ Pois(λ) + 1. The 1 unit shift from the standard
Poisson distribution avoids generating an empty tree, and the hyper parameter λ
controls the complexity of the resulting tree structure. Moreover, we assume that
an internal node u has ku(T )) terminal nodes; each of these terminal nodes can be
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assigned to the left or the right child node of u following a prespecified distribution.
Thus, we can simplify the process as
pi(T ) = α(k(T ))
∏
u∈a(T )
β(ku∗(T ) | ku(T )),
where α(·) is the Poisson distribution that controls the tree size; k(T ) denotes the
tree size. The conditional distribution β(ku∗(T ) | ku(T )) dictates the shape of the
tree, where ku(T )) is the number of available terminal nodes at internal node u and
ku∗(T ) is the number of nodes sent to the left child node u∗ of u. The tree-growing
process stops when ku(T ) = 1 at any node u. In general, β(·) controls the preference
of skewness of a tree and α(·) governs the preference of the tree complexity. More
details of the distribution specification of β(·) and α(·) can be found in Wu et al.
(2007).
For a given tree skeleton T , the distributions of pi(ρ | T ) and pi(η | ρ, T ) are
set to be uniform; i.e., each variable has equal probabilities of being selected and
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